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SUMMARY
In order to delineate the role of the lipid mediators, platelet-activating factor
(PAF) and leukotnene B4 (LTB4) in regulating polymorphonuclear neutrophil (PMN)
and plasma extravasation at sites of acute inflammation, we used selective and potent
PAF and LTB4 receptor antagonists in a rat dermal inflammation mode!. Briefly, rats
were injected subcutaneously with fiigrastim (Neupogen) for 9-11 days before the
experiment in order to raise the number of PIVIN circulating in the blood. Rats were
then pretreated orally with UK-74,505 or SR-27417 (PAF receptor antagonists)
and!or CP-105,696 (LTB4 receptor antagonist). Agonists under investigation,
including LTB4 and PAF were injected intradermally at duplicate sites in each rat.
Myeloperoxidase, an enzymatic marker contained in PMN azurophulic granules, was
used to assess local PMN accumulation whiÏe the Evans blue dye was used to
quantify plasma extravasation. In some experiments, local microcirculatory blood
flow was assessed by laser-doppler blood flowmetry.
In a series of experiments, we studied the role of PAF and/or LTB4, as well as
their potentially co-operative effect on PMN accumulation. b this end, rats were
pretreated witli either a selective PAF or LTB4 receptor antagonist, or with both
drugs, prior to intradermal injections of PAF and LTB4 to induce cutaneous
inflammation. Interestingly, the resuits show an additive inhibitoiy effect of LTB4-
and PAF-receptor antagonists on PAF-elicited PMN accumulation, suggesting a role
for LTB4 in regulating, at least in part, PAF-induced PMN extravasation at the blood
endothelium interface. In contrast, we did flot observe an additive effect of the dmgs
when LTB4 was used as a stimulus to elicit PMN accumulation in rat skin. In this
particular series of experiment, the LTB4 receptor antagonist CP-105,696 inhibited
LTB4-stimulated PMN accumulation by 79% at the dose used, which may have
precÏuded the observation of co-operative effect of agonists. Further studies are
undergoing to elucidate this point.
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In a second series of experiments, we investigated the role of PAF andlor
LTB4 in the chemotactic effect of a number of chemically unrelated soluble mediators
on PMN accumulation to dermal inflammatory sites. Our resuits support that PAF
andJor LTB4 contribute, at least in part, to dermal inflammation elicited by TNF-cL
and zymosan-activated plasma, the latter used as a source of C5iesarg. In contrast, the
lipid mediators PAF and LTB4 do flot appear to contribute to IL-8-elicited PMN
chemotaxis in vivo in rats. These resuits flirther support our working hypothesis that
LTB4 and PAF biosynthesis at the bÏood-endothelium interface may act in an
aurocrine or paracrine fashion to regulate events that are crucial to the PMN
transmigration pfocess. Inasmuch as plasma extravasation is a phenomenon
accompanying PIVEN diapedesis to the inflammatory sites, we have assessed the
contribution of PAF and/or LTB4 to plasma exudation elicited by inflammatory
mediators including PAF, LTD4 and substance P. Our results support that PAF and/or
LTB4 contribute, at least in part, to plasma extravasation elicited by LTD4.
The results obtained in this work support a role for PAF and/or LTB4 in
regulating PIVIN extravasation elicited by a number of inflammatoiy mediators at the
blood-endothelial interface. Furthermore, PAF and LTB4 may co-operate to this aim,
inasmuch as PAF and LTB4 receptor blockade had an additive effect in reducing
PMN accumulation elicited by either agonist in vivo. Our observations open a new
perspective to ffirther investigate the role of these lipid mediators in pathologic
inflammatory settings.
Key words chemotaxis, dermal inflammation, laser-doppler, LTB4, myeloperoxidase,
oedema, PAF, PMNs accumulation, rats.
VRÉSUMÉ
Dans le but d’ étudier le rôle des médiateurs lipidiques, notamment le facteur
d’activation plaquettaire (PAF) et le leucotriène B4 (LTB4) dans la régulation de la
migration des neutrophile polymorphnucléaire (PMN) et de l’extravasation
plasmatique aux sites d’inflammation aiguè, nous avons utilisé des antagonistes
sélectifs des récepteurs du PAF et du LTB4 dans un modèle d’inflammation
dermique chez le rat. Brièvement, les rats ont reçu des injections sous-cutanées de
fiigrastim (Neupogen”) pendant une période de 9 à 11 jours avant de débuter le
protocole expérimental afin d’augmenter le nombre des PMNs circulants dans le
sang. Les rats ont été prétraités oralement avec des antagonistes sélectifs des
récepteurs du PAF (UK-74,505 ou SR-27417) et/ou par un antagoniste sélectif des
récepteurs du LIB4 (CP-105,696). Les agonistes pro-inflammatoires à l’étude,
incluant le LTB4 et le PAF, ont été injectés par voie intradermique en duplicata sur la
région dorsale de chaque rat. La myelopéroxidase, une enzyme contenue dans les
granules azurophiles des PIVINs a été utilisée comme marqueur afin de déterminer la
quantité de PMNs présents dans les biopsies, tandis que le bleu d’Evans a été utilisé
pour quantifier l’oedème tissulaire. Dans quelques expériences, nous avons déterminé
le flux sanguin microcirculatoire à l’aide d’un moniteur laser-doppler «laser-doppler
bÏood flowmetry ».
Dans une première série d’expérience, nous avons étudié le rôle du PAF et/ou
du LTB4 et leur effet coopératif potentiel chez les rats prétraités avec un antagoniste
sélectif du PAF et/ou du LTB4. Les résultats ont montré qu’il y a un effet inhibiteur
additif des antagonistes du LTB4 et du PAF sur la migration extravasculaire des
PMNs induite par le PAF, ce qui suggère une rôle régulateur pour le LTB4 dans la
régulation de la migration des PIVINs à l’interface neutrophiles-cellules endothéliales
au niveau des vaisseaux sanguins. Par contre, nous n’avons pas observé d’effet additif
des antagonistes lorsque le LTB4 a été utilisé comme stimulus pour induire
l’accumulation dermique des PIVItIs. Dans cette dernière série d’expériences,
l’antagoniste CP- 105,696, sélectif pour les récepteurs du LTB4 administré seul , a
réduit de façon importante l’accumulation des PMNs induite par le LTB4 (79%), ce
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qui a pu limiter l’observation d’une action coopérative entre les agonistes. Des études
sont en cours présentement pour évaluer cette possibilité.
Dans une deuxième série d’expériences, nous avons étudié le rôle du PAF et
du LTB4 dans l’effet chimiotactique de plusieurs médiateurs solubles de nature
chimique différente. Nos résultats montrent que le PAF et/ou le LTB4 contribuent, du
moins en partie, à l’effet chimiotactique induit par le TNF-Œ et le plasma activé par le
zymosan (ZAP) utilisé comme source de C5a&sarg. À l’opposé, les médiateurs
lipidiques PAF et LTB4 ne semblent pas contribuer à la chimiotaxie des PMNs
induite par l’IL-8 in vivo chez le rat. Ces résultats supportent notre hypothèse de
travail selon laquelle la biosynthèse du LTB4 et du PAF au niveau de l’interface
leucocytes-cellules endothéliales, et leurs effets de nature autocrine ou paracrine,
peuvent moduler certains événements dans le processus de transmigration des PMNs.
Étant donné que l’extravasation du plasma est un phénomène qui accompagne la
diapédèse des PMNs au site inflammatoire, nous avons étudié la contribution du PAF
et/ou du LTB4 dans l’exsudation de plasma induite par des médiateurs inflammatoires
tels que le PAF, le LTD4 et la substance P. Nos résultats montrent que le PAF et/ou
LTB4 contribuent, au moins en partie, à l’extravasation plasmatique induite par le
LTD4.
Les résultats obtenus dans ce travail appuient un rôle du PAF et du LTB4 dans
la régulation de l’extravasation des PMNs induite par plusieurs médiateurs
inflammatoires au niveau de l’interface neutrophile-endothélium vasculaire. De plus,
le PAF et le LTB4 peuvent coopérer ensemble à cette fin. Nos observations ouvrent
de nouvelles perspectives pour l’étude du rôle des ces médiateurs lipidiques dans des
situations pathologiques inflammatoires.
Mots clés: chimiotaxie, inflammation dermique, laser-doppler, LTB4,
myelopéroxidase, oedème, PAF, accumulation des PMNs, rats.
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CHAPTER I: INTRODUCTION
Chapter 1: Introduction 2
Inflammation
1.1. The inflammatory response
Inflammation, a complex homeostatic reaction of the body, is a localized,
protective response to trauma or microbial invasion that destroys, dilutes, or wails-off
the injurious agents and the injured tissue. This response requires innate immunity
and, in some cases, an adaptive immune response, which are the two main integral
components of the host’s defence system. Innate immunity flot only acts as the first
une of defence against noxious material, but afler recognition of an appropriate
stimulus, it provides the necessary signais to instmct the adaptive immune system to
mount a response. In turn, the adaptive response relies on the innate immune system
to provide the necessary effectors, in the form of phagocytes and granulocytes, to deal
with the initiating stimulus (Lawrence et al., 2002).
These responses involve cellular and molecular mechanisms and are
orchestrated in such a manner as to protect the organism from ffirther insuit and to
retum normal functions to the tissues (Gauldie, 1991). Early investigators considered
inflammation as a primary host defence system. However, inflammation may also
lead to debilitating diseases, such as arthritis and gout. Hence, the end point of an
inflammatory reaction may be beneficial or harmful.
Macroscopically, inflammation is characterized in the acute form by five
classic signs: ta) Heat (calor); increase in temperatufe is seen oniy in peripheral parts
of the body, such as the skin. It is due to increased blood flow (hyperaemia) through
the region, resulting in vascular dilatation and the delivery of warm blood to the area.
(b) Redness (rubor); an acutely inflamed tissue appears red, due to dilatation of small
blood vessels within the damaged area. (c) Swelling (tumor), swelling resuits from
oedema, the accumulation offluid in the extravascular space. (d) Pain (dolor); results
partly from the stretching and distortion of tissues due to inflammatoiy oedema and,
in particular, from pus under pressure in an abscess cavity. (f) Loss of function
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(functio laesa); movement of an inflamed area is consciously and reflexly inhibited
by pain (figure 1.1). These signs have been known since the ancient Greek and
Roman era (Dennis et al., 1976; Gauldie, 1991; Walker and Fantone, 1994).
1.1.1. The phases of inflammation
Inflammation can be divided into several phases. The earliest, gross event of an
inflammatoiy response is temporary vasoconstriction, e.g., narrowing of blood
vessels caused by contraction of smooth muscle in the vesse! walls, which can be
seen as blanching (whitening) of the skin. This is followed by several phases that
occur over minutes, hours and days later, as following:
Acute vascutar response follows within seconds of the tissue injury and
last for some minutes. It resuits from vasodilation and increased capillary
permeability due to alterations in the vascular endothelium, which leads to
increased blood flow (hyperaernia) that causes redness (eiytherna) and the
entry of fluid into the tissues (oedema).
Acute cellutar response takes place over the next few hours. This phase
occurs if there is sufficient damage to the tissues, or if infection has
occurred. The appearance of granulocytes, particularly neutrophils, in the
tissues is the specific sign of this phase. if the vessel is damaged,
fibrinogen and fibronectin are deposited at the site of injury, platelets
aggregate and become activated, and the red celis stack together to help
stop bleeding and aid dot formation. The dead and dying celis contribute
to pus formation.
Chronic cettular response may follow during the next few days. It is
characterized by the appearance of a mononuclear ceil infiltrate composed
of macrophages and lymphocytes. The macrophages are involved in
microbial killing and in clearing up cellular and tissue debris.
Macrophages also seem to be very important in tissue remodeling.
Resotution, during which the normal tissue is restored as the blood dots
are removed by fibrinolysis where possible, or scarring as a resuil of in-
Chapter J: Introduction 4
Figure 1.1. Cardinal signs of inflammation
This cartoon depicts five Greeks representing the cardinal signs of
inflammation: heat, redness, swelling, pain and loss of function, which are as
appropriate today as they were when first described by Celsus more than 2000
years ago. This figure was commissioned by D.A.W. and drawn by P. Culi for
the Medical Illustration Department at St Bartholomew’s Medical College.
from Lawrence et al., Nature Reviews IrnrnunoÏogy 2, 787-795, 2002.
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fihling with fibroblasts, collagen, and new endothelial celis (ECs).
Generally, by this time, any infection will have been overcomed.
In acute inflammation, the hydrostatic pressure in postcapillary venules may
overcome the osmotic pressure of plasma proteins. Therefore, fluid and low
molecular substances have the tendency to penetrate into the surrounding area. The
increased capillary permeability for plasma proteins is the key factor for the
production of inflammatory exudate. In the interstitial area, high-molecular weight
proteins may be spiit into smaller fragments that participate in the raising of the
osmotic pressure of interstitial fluid.
Cellular exudate is formed during the second and the thfrd phase of
inflammation, e.g., acute and chronic cellular responses. During the former,
neutrophils are prevatent, whereas mononuclear celis (macrophages and
lymphocytes) are predominant in later phases. Celi composition ofexudate differs not
only depending on the phase of inflammation, but also on the type ofinflamed tissue
and on the factors tfiggering the inflammatory process. Central effector and
regulatory functions in acute inflammation rely on neutrophils. Eosinophils and
basophils may also be involved. So, a number of different celi types are potentially
recwited into the area where damage has occurred, and these are responsible for
inactivation and removing of invading infectious agents and damaged tissues, as well
as for inducing the formation of new tissue and reconstructing the damaged celi
matrix, including basement membranes and connective tissue. A new blood supply to
the area is also established during the repair process Martinez-Hemandez, 2001).
1.1.2. The response to injury and infection
The celis of the immune system are widely distributed throughout the body,
but, if an infection or tissue damage occurs, it is necessary to concentrate them and
their products at the site of injury. As discussed above, three major events occur
during this response:
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• An increased blood supply to the tissue in danger” (vasodilatation). The
inflamed tissue looks like containing a greater number ofvessels.
• Retraction of the endothelial celis (EC5), allowing larger molecules than
usual to escape from the capillaries, and thus, allowing the soluble
mediators of immunity to reach the site of inflammation.
Migration of leukocytes out of the capillaries into the surrounding tissues
(Walker and fantone, 1994).
Inflammatory responses must be well-ordered and controlled. Therefore, a
wide variety of interconnected cellular and humoral (soluble) mechanisms are
activated when tissue damage and infection occur. Celis and inflammatory mediators
participating in these events are detailed in the following paragraphs.
1.2. Ceils parficipafing in acute inflammation
1.2.1. Mast celis and basophils
Mast ceils are localized within the connective tissue of the body, whereas
basophils are present in low number in the circulation. They play a central role in a
variety of inflammatory and allergic conditions; they are able to release potent
inflammatory mediators such as histamine, proteases, chemotactic factors, cytokines
and metabolites of arachidonic acid from the dense cytoplasmic granules into
extracellular tissues by degranulation (Fantone and Ward, 2001). The degranulation
could be induced by: (a) a physical destruction such as mechanical trauma; (b)
chemicaÎ substances, such as toxins and proteases; (e) ceil mediators, peptidases and
peroxidases such as cationic proteins derived from eosinophils and neutrophils; (d)
immune mechanisms which may be immunoglobulin (1g) E-dependent or IgE
independent. Botb, eosinophils and basophils contain high affinity receptors (FcRl)
for IgE on their surface which can be triggered during the IgE-dependent mechanism.
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In the IgE-independent way, the anaphylatoxïns C5a, C3a and C4a, formed during
activation of complement, trigger degranulation through C5a celi surface receptors.
1.2.2. Eosinophils
The eosinophil is a tenninally differentiated, end-stage leukocyte that resides
predominantly in the submucosaÏ tissue and is recmited to sites of specific immune
reactions, including allergic diseases. Its cytoplasm is fihled with large eosinophilic
granules and its nucleus is almost aiways bilobed although trilobed forms are
sometimes seen (Bainton, 1999). The granules are the principal identifying feature of
eosinophils. They contain four distinct cationic proteins which exert a range of
biological effects on host ceils and microbial targets: major basic protein, eosinophil
cationic protein, eosinophil derived neurotoxin, and eosinophil peroxidase. In
addition, histaminase and a variety of hydrolytic lysosomal enzymes are also present
in the large specific granules (Peters et al., 1986). Recently, it has been recognized
that eosinophils are capable of elaborating cytokines like granuÏocyte-macrophage
colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) and IL-5, (Kita et al., 1991;
Desreumaux et al., 1993) as well as chemokines such as eotaxin (Ponath et aÏ., 1996),
which play a roÏe in inflammatory responses. Eosinophils also synthesize lipid
inflammatory mediators, in particular leukotriene C4 (LTC4) and platelet-activating
factor (PAF). Both mediators contract airway smooth muscle, promote the secretion
of mucus, alter vascular permeability and elicit eosinophil and neutrophil infiltration
(Lewis and Austen, 1984; Lee et aL, 1984).
1.2.3. Polymorphonuclear neutrophits
Polymorphonuclear neutrophils (PMNs) represent 50 to 60% of the total
cfrculating leukocytes in the normal adult human and constimte the t’first line of
defence’1 against infectious agents or ‘Tnon-self’ substances that penetrate the body’s
physical barriers. Their targets include bacteria, fungi, protozoa, viruses, and tumor
ceils. The neutrophils are spent in three environments, including bone marrow, blood
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and tissues. Bone marrow is the site of the important processes of the proliferation
and terminal maturation of neutrophilic granulocytes before being released to the
circulation (Bainton, 1999).
Neutrophils are terminally differentiated ceils rich in cytoplasmic granules
and containing a lobulated chromatin-dense nucleus with no nucleolus; the nucleus of
the mature neutrophil is segmented into three to five interconnected lobes. The bone
marrow of a normal heahhy aduit produces more than 1011 neutrophils per day and
more than 1012 per day in settings of acute inflammation. Upon release from the bone
marrow to the circulation, the ceils are in a non-activated state and have a haif-life of
only 4 tolO h before marginating along the vessel walls and entering tissue poois,
where they survive for 1 to 2 days. Celis of the circulating and marginated pools can
exchange with each other. Senescent neutrophils are thought to undergo apoptosis
(programmed ceil death) prior to removal by tissue macrophages (Saviil et al., 1993).
The rate of neutrophil egress ftom the bone marrow is controlled by several factors,
such as infection, stress and also by two colony-stimulating factors, granulocyte
colony stimulating factor (G-C$f) and GM-CSf. Both factors direct the production
and differentiation of bone marrow progenitor ceils. The rate of the neutrophil
differentiation can increase as much as 1 0-fold during state of stress and infection
(Cannistra and Griffin, 198$).
1.2.3.1. PMN granules
The initial classification into two major types of neutrophil granules was
based on their content in myeloperoxidase. However, the granules can be subdivided
into four distinct populations, azurophil, specific, gelatinase, and secretory, as
summarized by Borregaard and Cowiand (1997). These populations (table 1.1) have
been identified by cytochemical, immunocytochemical, and celi ftactionation
procedures.
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Azurophil granules are known to contain myeloperoxidase (MPO), an
antibacterial enzyme, and other numerous antimicrobial agents, lysozyme, and
lysosomalenzymes (Bretz and Baggiolini, 1974). Defensins, azurophil-derived
bacterial factors, and bactericidal permeability-increasing protein are bactericidal
factors have been found in some azurophil granules (Rice et al., 1987; Gabay et al.,
1986; Weiss and Olsson, 1987). In the azurophil granules ofhuman PMNs, cathepsin
G, elastase, proteinase-3, and azurocidin are antimicrobial proteins which collectively
could be called “serprocidins” and are closely related to serine proteases with
microbicidal activity (Gabay et al., 1989). Specific granules, peroxidase-negative
granules, which by definition do not contain peroxidase, contain lysozyme (Cramer
and Breton-Gorius, 1987), lactoferrin (Bretz and Baggiolini, 1974), B12-binding
proteins (Kane and Peters, 1975), and others as shown in table 1.1 (Bainton, 1999).
The limiting membrane of specific granules and/or intracellular vesicles serves as a
reservoir of receptors and other proteins involved in adherence, signal transduction,
and functional activation ofmicrobicidal pathways (Bainton et al., 1987). Gelatinase
granules are a subgroup of small, peroxidase-negative specific granules. They are
defined by their high content of gelatinase (Borregaard and Cowiand, 1997).
Secretory granules were originally discovered as highly mobilizable intracellular
vesicles that contain alkaline phosphatase on their luminal surface (Borregaard et al.,
1990). Mthough many studies have assumed that alkaline phosphatase was a plasma
membrane marker, it seems instead to be in a cytoplasmic organelle, distinguishable
from azurophil-, specific-, and gelatinase-containing granules, which is easily
mobilized to the surface(Kobayashi and Robinson, 1991).
Among azurophul granule constituents, MPO is a critical enzyme converting
hydrogen peroxide (H202) to hypochiorous acid. Together with hydrogen peroxide
and a halide cofactor, MPO system forms the most effective microbicidal and
cytotoxic mechanism of leukocytes. IVPO is responsible for the characteristic green
color of pus (Klebanoff 1999).
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Azurophil granules Specific granules Gelatinase granules Secretory vesicles
Membrane Membrane Membrane Membrane
CD63 CD1 lb CD1 lb Mkaiine phosphatase
CD6X Cd15 antigens Cytochrome b558 CRi
V-type }{-ATPase CD66 Diacylglycerol- Cytochrome b558
CD67 deacylaling enzyme CD 1 lb
Cvtochrome b558 FMLP-R CD14
FMLP-R SCAMP CDl6a
Fibronectin-R Urokinase-type FMLP-R
G-protem subunit plasminogen activator-R SCAMP
Lamiiiin-R VAMP-2 Urokinase-type
NE-l antigen V-type W-ATPase plasminogen acfivator-R
1 9-kd protein V-type W-ATPase
155-kd protem VAMP-2
Rapl, Rap2 CD 10, CD13, CD45a
SCAMP Clq-receptor
Thrombospondm-R DAF
TNF-R
Urokinase-type
plasminogen aclivator-R
VAMP-2
Vitronectm-R
Matrh Matnx Matrix Matnx
Acid [32-Microglobulm Acetyltransferase Plasma proteins (mcluding
f3-glycerophosphatase Collagenase f2-Microg1obuhn albumin and tetranectin)
Acid mucopolysaccharide Ge1athase Gelatmase
ci1-Antitiypsin hCAP-18 Lysozyme
a-Mannosidase Histaminase
AzurocidinlCAP37l Heparanase
hepann-binding protein Lactoferrin
Bactericidal penneabfflty Lysozyme
increasmg protein NAGL
f3-Glycerophosphatase Urokinase-type
f-Glucuromdase plasminogen aclivator
Cathepsms Sialidase
Defensins SGP2S
Elastase Vitawin B12-binding
Lysozyme protem
Myeloperoxidase
N-acetyl- -glucosaminidase
Protinase-3
Sialidase
Ubiquitin-protein
Table Li. The content ofhuman neutrophil granules ami secretoiy vesicles
From Bainton, DeveÏopmental biology of neutrophils and eosinophils. In
b?flarnrnation: Basic Principle and Clinicat Correlate 3rd ed, 1999.
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1.2.3.2. PMNs in host defence
The major role of neutrophils is to phagocytose and destroy infectious agents
or celis, but they also limit the growth of some microbes, thereby buying time for
adaptive (specific) immunological responses.
Phagocytosis is a complex process that involves several biochemical steps.
Phagocytosis is triggered upon binding of opsonized or unopsonized microorganism
through opsonin receptors (for complement fragments and antïbodies) or tbrough
nonspecific glycosylated receptors that recognize certain lectins on target
microorganism (Smith, 1997).
During phagocytosis, cytosolic granules (lysosomes) fuse with the
invaginating plasma membrane (around the engulfing microorganism) to form a
phagolysosome into which they release their contents, thereby creating a highly toxic
microenvironment (figure 1.2). This normally prevents the release of the
microbicidal components into the extracellular milieu. However, some targets may be
too large to be phagocytosed, resulting in frustrated phagocytosis in which no
phagosome is formed, and which may lead to the secretion of the cytosolic granules
content into the eKtracellular milieu, where the targets may be killed (Kiebanoif,
1999).
The other microbicidal mechanism is the oxidative mechanism (oxidative
burst), so called because ofthe 50-100 fold increase in 02 consumption which resuits
in the production of the superoxide anion (02) and other cytotoxic reactive oxygen
species (ROS) and, potentially, reactive nitrogen species (RNS). 02 is formed,
initially, by the reduction of molecular oxygen by a single electron that originates
from NADPH; this process is catalyzed by the combined action of the plasma
membrane NADPH oxidase and cytochrome b558. Mthough 02 may contribute to
microbial killing, additional more potent ROS are generated from this precursor sucli
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as H202 which is formed by the spontaneous dismutation of 02 and/or the catalytic
action of superoxide dismutase (SOD) (Smith, 1994). 11202 react with the abundant
CF ions taken up from extracellular fluid to generate hypochiorous acid (HOC1), a
reaction catalyzed by MPO contained in azurophil granules (Smith, 1997).
Nitric oxide (N0), which derived from the guanidino nitrogen in the
conversion ofL-arginine to L-citmlline, may contribute to the microbicidal activity of
neutrophils by reacting with ROS to form secondary cytotoxic species such as
peroxynitrite (00N02) (McCall et ai, 1989).
1.2.3.3. PMNs and host tissue damage
While neutrophils are essential to host defence, they have also been
implicated in many pathologic inflammatory conditions and in ischemia-reperfusion
injury (Weiss, 1989; Ricevuti et al., 1991).
Host tissue damage may occur through several independent mechanisms.
Ihese incÏude: premature activation during migration, extracellular release of toxic
products during the killing of microbes or during removal of infected or damaged
host ceils, and debris as a first step in tissue remodeling, or as a failure to terminate
acute inflammatory responses (Smith, 1994; Smith, 1997).
for example, neutrophils have been implicated in the pathology of the aduit
respiratory distress syndrome (ARDS) because of large influx of these ceils into the
lung and the associated tissue damage caused by oxidants and hydrolytic enzymes
released from activated neutrophils (Martin et al., 1991). Activation ofthe neutrophils
by immune complexes in synovial fluid contributes to the pathology of rheumatoid
arthritis (Robinson et al., 1992). Chronic activation of neutrophils may also initiate
tumor development because some ROS generated by neutrophuls damage
deoxyribonucleic acid (DNA) in vitro (Weitzman and Gordon, 1990).
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1.2.3.4. PMN priming
Neutrophils may show three distinct states: dormant, primed, and activated.
Priming means the neutrophiÏ’s functional responses (e.g., ROS production,
chemotaxis) to a stimulus are amplified by previous exposure ofthe ceil to a priming
agent. The priming agent, at low concentration, does flot normally cause a noticeable
functional response (Guthrie et al., 1984; Bass et al., 1987; Swain et al., 2002).
furthermore, there is al so evidence that primed neutrophuls can retum to a resting
state (Kitchen et al., 1996).
The priming agents include bacterial products like lipopolysaccharide (LPS),
muramyl dipeptide (IVDP) and peptidoglycan, lipotechoic acid and N-fonnyl
methionyl-leucyl-phenylalanine (fMLP); products from fungi like glucan and
mannan; lipid mediators like leukotriene B4 (LTB4) and PAF; and cytokines like
interleukin-8 (IL-8) and tumor necrosis factor- Œ (TNF-Œ) (Pabst, 1994).
Neutrophil priming is thought to play a key role in host defence process, and
the regulation of priming may be essential for host survival. A number of studies
have suggested that priming may be a good indicator of clinical disease activity.
Enhanced neutrophil ROS production has been reported in patients with infection
(Solberg et al., 1982). Primed neutrophuls have also been found in the blood of
trauma patients (Zallen et al., 1999), as well as in patients with chronic inflammatory
disease such as rheumatoid arthritis (Eggieton et al., 1995).
1.2.35. Mechanisms ofPMN extravascular accumulation
Circulating leukocytes can migrate from vessels into tissues under both
normal and pathologic circumstances. The neutrophil migration from vasculature
occurs by a multistep process (figure 1.3), dictated by sequential activation of
adhesive proteins and thefr ligands on both leukocytes and ECs (von Andrian et al.,
1991). In postcapillary venules, the blood flow slows following injury and leukocytes
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migrate to the endothelial surface. Initiation of the migration begins with the
“capture” of PMNs from flowing blood by the vessel wall, and this is foflowed by
their “rolling” along the vessel wall.
1.2.3.5.1. Capture and rolling ofleukocytes
Both the capture and rolling of leukocytes along the vessel wall is due to the
reversible binding of transmembrane glycoprotein adhesive molecules caÏled
selectins, which are found on both PMNs and ECs. Selectins have three major
domains, of which the extracellular lectin domain is involved in ligand binding, an
epidermal growth factor-like domain and a varying numb ers of short consensus repeat
domain (SCR) that keep selectins away from the ceil surface (Crockett-Torabi and
fantone, 1995). There are tbree types of selectins; the teukocyte setectin (L-selectin)
appears to be critical for the rolling process. In addition, there are two endothelial
selectins, the ptatetet setectin (P-selectin), which is rapidly and transiently expressed
on ECs, and the endotheliat setectin (E-selectin), which appears a few hours later.
The endothelial selectins are expressed only when appropriate inflammatory stimuli
are present and interact with their PMN counterpart, which is a complex glycoprotein
caïled P-selectin glycoprotein Iigand-1 (PSGL-1), belonging to the family of
sialomucines (McEver and Cummings, 1997; Wagner and Roth, 2000).
1.2.3.5.2. Integrin-mediated firm adhesion
Cytoplasmic domains of bound L-selectin and PSGL-1 are linked to signal
transduction pathways that lead to integrin activation in PIVINs (Crockett-Torabi and
Fantone, 1995). Integrin activation is associated with the next step of the migration
process, which is the firm adhesion ofthe leukocyte on ECs surface (figure 1.3). The
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inregrins are a group of heterodimeric transmembrane glycoproteins found on PMNs
and other hematopoietic ceils that mediate ceil-ceil or ceil-extracellular matrix (ECM)
adhesion. There are 18 different integrins Œ-chains and 8 different f3-chains which
pair together in specific pattem depending on the ceil type (Travis et al., 2003). PMN
binding to activated endothelium is mediated mainly by two integrins: macrophage
antigen-1 (MAC-1), also known as ŒMf32 or CD1 lb/CD1$, and lymphocyte
associated fiinction antigen-1 (LFA-1), also known as ŒLf32 or CD1 ÎaJCD18 (figure
1.4). The importance of the integrin-mediated adhesion process is illustrated in
patients with leukocyte adhesion deficiency syndrome (LAD-1), characterized by the
absence of the f32 (CD 18) chain, which show severe recurrent, and life-threatening
bacterïal infections secondary to an inability to locally recruit PIv[N (Anderson and
Springer, 1987).
The major counterligands ofintegrins belong to the immunoglobulin (7g)-liked
superfamiÏy of adhesive rnotecules characterized by the presence of one or more
immunoglobulin homology regions in their structure. IntercelluÏar adhesion
molecule-I (ICAM-1), a member ofthis superfamily, is an important complementary
endothelial ligand for MAC-1, exhibiting low constitutive presentation on EC
membrane which is markedly induced by exposure ofECs to inflammatory cytokines
(ligo et al., 1997). LFA-1 can also bind to ICAM-1, but it bas higher affinity to a
related protein, ICAM-2, a ligand to which MAC-1 binds with low afflnity (Wagner
and Roth, 2000). Vascular ceil adhesion molecule-1 (VCAM-1) is also an Ig-like
molecule on ECs, but it binds selectively to f31-integrins such as cx4f3i integrin also
called very late antigen-4 (VLA-4), which is critical for the migration of monocytes
and eosinophils. However, VLA-4 has also been identified in both activated human
and rat PMNs and may mediate VCAM-1-dependent adhesion of PMNs to
endothelium in vitro (Davenpeck et al., 1998). A summary of integrin, selectin and
Ig-like superfamlly ofadhesion molecules is found in table 2.1 (Horton, 1996).
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1.2.3.5.3. PMN diapedesis
Subsequent to the firm adhesion, diapedesis of the PMN at endothelial celis
junctions occur in a platelet endothelial ce!! adhesion molecule-1 (PECAM-1) or
CD3 1-dependent manner. PECAM-1 is found on PMNs, platelets and ECs, serve as
its own ligand and form homodimers with molecules on opposing celis. PECAM-1 is
hypothesized to be a homing receptor to localize the transendothelial route for the
migrating PMN. Treatment of the PMN or endothelial monolayers with an antibody
to PECAM-1 blocks transmigration in vitro (Muller et ai, 1993).
1.2.3.5.4. PMN migration in the extravascular space
PMNs possess proteases capable of digesting collagen, laminin, and other
extracellular components present in the vascular wall. Adhesion and migration are
accompanied by the release of PMN-derived proteases (Hanlon et al., 1991).
However, Mackeral et al. found that protease inhibitors are ineffective in stopping
PMN migration through intact endothelial monolayers and basement membranes in
vitro. Thus, the requirement for protease release is uncertain (Mackarel et al., 1999).
Interaction of PMN f31—integrin with ECM proteins is important for transit of
PMNs through the extravascular milieu. for example, PMN migration through the
lung or synovial fibroblast barriers has been shown to require not only CD 1$ (132) but
also VLA-4, VLA-5 (ci13i), VLA-6 (a3i) and VLA-9 (Œ9131), wbich are the most
highly expressed f31—integrins in PMN, to bind the ECM components (Shang and
Issekutz, 1997).
PECAM-1 is also involved in the extravascular transit of leukocytes. But
unlike the homotypic interaction between PECAM molecules that mediate homing
and diapedesis, migration through the subendothelial environment requfres
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heterophilic binding of leukocytic PECAM-1 to an unidentified ligand (Wakelin et
al., 1996).
1.3. Inflammatory mediators
When leukocytes reach the site of infection or inflammation, they release
mediators which control leukocyte accumulation and activation ofneighboring ceils.
Inflammatory mediators are soluble molecules that act locally at the site of
tissue damage and infection, and at more distant sites. These mediators may be low
molecular weight proteins like cytokines and chemokines, hormones like
neuroendocrine hormones, growth hormone and prolactin, or bioactive lipids like
arachidonic acid and their metabolites (Smith, 1994).
Inflammatory mediators can be divided into exogenous and endogenous
mediators. Exogenous mediators, such as bacterial products and toxins, evoke
poweiful responses. For example, LPS can trigger complement activation, resuhing
in the formation of the anaphylatoxins C3a and C5a which cause vasodilation and
increase vascular permeability. LPS also activates the Hageman factor, leading to
activation of the coagulation and fibrinolytic pathways as well as the kinin system. In
addition, it elicits T celi proliferation, and has been described as a superantigen for T
ceils. Endogenous mediators of inflammation are produced from the immune
system (innate and adaptive) itself as well as from plasma. For example, they can be
derived from molecules that are normally present in the plasma in an inactive form,
such as peptide fragments of the complement, coagulation, and kinin systems.
Mediators of inflammatoiy responses are also synthesized by a number of celi types
that contain them as preformed molecules within storage granules, e.g. histamine, or
which can be rapidly synthesized when they are required, for example, metabolites of
arachidonic acid such as LTB4, LTC4 and leukotriene D4 (LTD4).
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Inflammatory mediators can also be classified into early and late phase
mediators (White, 1999). Early phase mediators are important in acute
inflammation and include histamine, serotonin and other vasoactive substances. They
are produced by mast celis and platelets. In addition, lipid mediators, chemoatractants
(e.g. C5a) and cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and TNF-Œ
belong to the eafly phase mediators. Late phase mediators are found 6-12 hours
afier initiation of inflammation. They are responsible for the regulation of vascular
events. The later vascular events are mediated, at least in part, by products of
arachidonic acid such as prostaglandin E2 (PGE2), LTD4 and LIC4.
Mediators which accumulate at local inflammatory sites such as skin blisters
are somewhat different from those released following intravenous endotoxin.
Mediators detected in blister fluid within 3 to 5 h of the inflammatory response
include LTB4, C5a, IL-8 and IL-6. In contrast, IL-1f3, GM-CSF, and TNf-a are flot
detected until afler $ hr in the blister. Afier i.v. endotoxemia, semm TNF reaches a
peak level in 90-120 minutes and subsequently declines, to become undetectable
within 4-6 h (Wang and Tracey, 1999).
1.3.1. ilistamine and Serotonin
They are the most important vasoactive mediators stored in mast ceil and
basophil granules; both of them are also present in human platelets. Histamine is
largely complexed to mucopolysaccharides such as heparin. Histamine has diverse
biological ffinctions including local dilatation of small vessels, widespread arteriolar
dilatation, local increased vascular permeability through ECs contraction, contraction
of nonvascular smooth muscle, chemotaxis for eosinophils, and blockade of T
lymphocyte function (Pearce, 1991). Serotonin is also capable of increasing vascular
permeability, dilating capillaries and producing contraction of nonvascular smooth
muscle.
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1.3.2. Cytokines and Chemokines
Cytokines are soluble polypeptides that mediate and regulate various aspects
of inflammation. The most important pro-adhesive cytokines that are present during
most inflammatory responses are TNF-a and IL-1. The primary cellular sources of
these mediators are macrophages and monocytes, and LPS is perhaps their most
important inducer (Di Girolamo et al., 1997). Neutrophils also synthesize and secrete
small amount of some cytokines including IL-1, IL-6, TNF-a, and GM-CSF, wbich
may act in an autocrine or paracrine manner (Lloyd and Oppenheim, 1992). PMNs
respond to TISF-o. by activating and expressing integrins, producing PAF and other
mediators, and releasing granule contents. Likewise, ECs can respond to TNF-a
exposure by mobilizing E-selectin, up-regulating ICAM-1 and activating
procoagulant pathways (Burke-Gaffney and Helleweli, 1996). It was found that
during inflammation and endotoxemia, PMNs release from their membrane a soluble
TNF-a receptor (p55) that can bind and effectively inactivate circulating TNF-a
(Wagner and Roth, 2000). IL-1 exerts similar physiological effects (Scholz et al.,
1996). Thus, the early appearance of TNF-ct and IL-1 in plasma during inflammation
is likely critical for the capture and firm adhesion ofPMNs to vascular endothelium.
Chemokines are a superfamily of low molecular weight cytokines with
selective chemotactic properties. They have been subdivided into families on the
basis of the relative position of their cysteine residues. The largest families are a
chemokine (cysteine-X amino acid-cysteine or CXC) and f3-chemokine (cysteine
cysteine or CC). IL-8, a member of the CXC superfamily, as well as macrophage
inflammatory protein-1 alpha (MW-la), macrophage chemoattractant protein-1,-2,
and -3 (MCP-1,-2,-3) and RANTES, which are members of the C-C superfamily,
function primarily as chemoattractant molecules for macrophage and circulating
leukocytes (Luster, 1998). Chemokines were first identified in vitro and initially
thought to be produced by activated macrophages and monocytes. However under the
proper conditions, their production and release has been elicited from neutrophils,
endothelium, and a variety of parenchymal ceils in vitro. For example, activation of
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neutrophils with particulate stimuli such as zymosan induces the generation of the
CXC chemokine IL-8 (Au et al., 1998). further studies suggest that these ceils
produce chemokines in animal modeis (Rovai et al., 199$). Chemokines are thought
to provide the signais that convert the iow-affinity, seiectin-mediated interaction into
the higher-affinity, integrin-mediated interaction that lead to extravasation of
leukocytes (Luster, 1998).
Rodents do flot have an IL-8 analog and, instead, possess cytokine-ïnduced
neutrophil chemoatracifants (CINCs). CNC-1, MLP-2, CLNC-2a and CINC-2f3 are
released from LPS-stimulated rat macrophages in vitro and possess similar ability to
elicit chemotaxis and degranulation of PMNs (Nakagawa et al., 1996). Rodents
respond to human IL-8 and the i.v. administration of IL-8 inhibits PMN migration to
extravascular sites of inflammation in rabbits (Ley et aI., 1993). Another in vivo study
showed that eosinophil accumulation in response to IL-1f3 was significantly
suppressed in rats treated with an anti-human IL-8 mAb DMJC7 (Sanz et ai., 1995).
Mthough LPS, TNF-Œ, and IL-Ï are flot chemoatactic for PMNs, their
exposure to cultured ceils can induce the production of chemoattractants such as IL-8
and PAF (Burns et al., 1997).
1.3.3. Products ofthe complement system
The complement system is a potent mechanism for initiating and amplifying
inflammation. This is mediated through activated fragments of complement
components. C3a, C4a and C5a are proteolytic products ofthe serine proteases ofthe
compiement system. These anaphylatoxins are polypeptides containing
approximately 75 amino acid residues. The C-terminal arginine in the molecule of
C3a is offundamental importance for its biological activity, whereas removal ofthe
C-terminal arginine ofC5a (CSacjesArg) only decreases its biological activity.
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The anaphylatoxins have powerful effects on blood vessel walls, causing
contraction of smooth muscle and an increase in vascular permeability. C5a is
extremely potent at stimulating neutrophil chemotaxis, adherence, respiratory burst
generation and degranulation (Kohi and Bitter-Suermann, 1993). Ligation of the
neutrophul C5a receptor at dermal skin sites is followed by mobilization of membrane
arachidonic acid which is primarily metabolized to LTB4, another potent
chemoattractant for neutrophils and monocytes, as obsewed in rabbits (Marleau et al.,
1999).
1.3.4. Lipid mediators
Lipid mediators are a class of lipid molecules derived from the metabolism of
membrane phospholipids. These include PAF and the vast array of eicosanoids,
which are derived ftom the metabolism of arachidonic acid (figure 1.5).
1.3.4.1. Leukocyte phospholipases
During inflammation, cellular phospholipases, especially phospholipase A2
(PLA2) and C, are activated and degrade phospholipids to induce mobilization of
fatty acids (FAs) from the membrane lipid pooi for the synthesis of lipid mediators at
the site of cellular damage or inflammation (Heller et al., 199$). The fAs composing
the normal inflammatory ceil membrane are saturated fAs, monounsaturated fAs,
and polyunsaturated FAs, the latter composed of omega-3 and omega-6 FAs, which
includes arachidonic acid (AA).
AA, the mother substance of pro-inflammatoiy eicosanoids, lias a short haif
life and can be metabolized by two major pathways, the cyclo-oxygenase (COX) and
lipoxygenase (LO) pathways. The COX pathway leads to the production of
prostaglandin (PG) H2 which can be further metabolized to PGE2, PGI2 (prostacyclin)
and thromboxane A2 (TXA2). These eicosanoids have potent local effects in the
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manifestation of inflammation. LO pathways lead to the production of leukotriene A4
(LTA4) which is further metabollzed into a number of leukotrienes: LTB4, LTC4,
LTD4 and leukotriene E4 (LTE4), which have potent pro-inflammatory effects.
Phospholipids can also be metabolized by induction of PLA2 activity to lyso-PAF
which is then converted to PAF (Braquet et al., 1991; Bulger and Maier, 2000).
PLA2 is a key enzyme in the production of lipid mediators from membrane
phospholipids as it catalyzes the hydrolysis of the sn-2 position of membrane
phospholipids to release unsaturated fatty acids. PLA2 enzymes fali into four broad
categories: the group W cytosolic PLA2 (cPLA2) calcium (Ca2)-dependent enzymes;
the low molecular weight, secretory enzymes (sPLA2), including many groups like
lB, HA, IIC, UD, 11E, 11F, ifi, V, X and XII; the Ca2tindependent, group VI
enzymes; and the selective acetyl hydrolases of PAF, groups VII and VIII PLA2
(Dennis, 1997; Diaz and Arm, 2003). cPLA2 is present in most celis and tissues
including PIvIN and monocytes, where it is critical to the production of PAF and AA,
thereby playing an important role in both rapid and prolonged cellular response
occurring during iiiflammatoiy processes. PLA2 activity is increased in response to
norepinephrine, adenosine, bradykinin, PAF, TNF, and IL-1 stimulation (Anderson
et al., 1994). In summary PLA2 groups and their properties are found in table 1.3 (Six
and Dennis, 2000).
Phosphatidylinositol-bisphosphate is a major phospholipid in eukaryotic celis
that can be hydrolyzed by PLC to diacylglycerol which is ffirther metabolized to AA
by diacylglycerol lipase (Fantone and Ward, 2001).
1.3.4.2. Prostaglandins (PGs)
PGs have been detected in almost ail experimentai models of inflammation
and clinical inflammatory conditions. For instance, the major PGs found in the
synovial fluid of patients with arthritis are PGE2 and PGI2. In leukocytes, they are
synthesized de nova ftom membrane-released AA when ceils are activated by
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Group Initial/common Alternate Size Ca2 effects Characteristics
sources names (kDa)
employed
W A Human U937 celis! cPLA2Œ $5 < iM; membrane C2 domain,
platelets RAW 264.7lrat transiocation aIf3-hydrolase
kidney regulatory
phosphoiylation
B Human pancreasfllver cPLA2f3 114 < iM; membrane C2 domam,
heartlbmin transiocation a/f3-hydrolase
C Human hearUskeletal cPLA2y 61 None Prenylated,
muscle a/f3-hydrolase
VI A-1 P388D1 macrophages, IPLA2 or $4-$5 None Short splice,
CHO iPLA2-A $ ankyrin repeats
A-2 Human B-lymphocytes, IPLA2-B $8-90 None Long splice,
testis 7 ankyrin repeats
B Human heartlskeletal iPLA2 « or 8$ None membrane-bound
muscle iPLA2-2
VII A Hmnan/mouse/porcine PAF-AH 45 None Secreted,
bovine plasma &3-hydrolase
Ser/His/Asp triad
in VIIA and B
B Human/bovine PAF-AH (11) 40 None Intracdllular,
hverflddney myristoylated
VIII A Human brain PAF-AfflbŒ1 26 None Intracelhular,
(suburnt of G protein fold
trimer) SerfHis/Asp triad,
dimeric
B Human brain PAF-AHIb c 26 None Same as VIII A;
(subunit of active as
trimer) heireodimer or
homodimer
Table 1.3. Superfamily ofPLA2 enzymes
From Six and Dennis. Biochim. Biophys. Acta, 1488, 1-19, 2000.
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mechanical trauma or by specific cytokines, growth factors, or other stimuli, and act
as autocrine and paracrine mediators.
1.3.4.2.1. Biosynthesis of PGs in leukocytes
At the endoplasmic reticulum and nuclear membrane, AA released by cPLA2
is presented to prostaglandin H synthase (PGHS), also known as COX for cyclo
oxygenase, to form an intermediate prostaglandin, PGH2 (Funk, 2001). PGHS exists
as two isoforms referred to as PGHS-1 (COX-1) and PGHS-2 (COX-2) (Smith et al.,
2000). In simplistic terms, COX-1 is the enzyme responsible for basal, constitutive
prostaglandin synthesis, whereas COX-2 is an inducible form of cyclooxygenase
stimulated in the setting of acute inflammation in response to various cytoldnes,
endotoxin and mitogens. Both enzymes catalyze the insertion of molecuÏar oxygen
into arachidonic acid at Cil and Cl 5 resuit in formation of PGG2, and then, catalyze
the reduction of PGG2 to PGH2 which is further metabolized by PG synthases into
PGD2, PGE2, and PGF2 The cellular expression pattern of each synthase may
profoundly influence the type of PG produced by particular celi. For example,
platelets produce predominantly TXA2; ECs produce PGI2 and mast ceil produce
PGD2 (Griffiths, 1999). In addition, monocytes produce mainly PGE2 through human
peripheral blood mononuclear ceils produce a factor (MCF) (Robinson et al., 1979).
The effect of PGE2 resuits from its binding to PGE2 receptor subtypes EP2
and EP4, which stimulate production of the second messenger cAMP (Yoshikai,
2001).
1.3.4.2.2. Role ofPGs in inflammation
PGs generated by the PLA2/COX pathway play a dichotomous role in acute
inflammation. PGE2 at physiological concentrations may be pro-ïnflammatory during
the early phase of acute inflammation, while other PGs may regulate the resolution of
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acute inflammation. PGE2 for instance, produced by macrophages (and ECs),
contribute to the local vasodilation. PGE2 also downregulate macrophage response to
cytokine stimulation (Fink, 1998). PGE2 concentration at inflammatory sites may
determine whether its effect is pro- or anti-inflammatory; high concentrations of
PGE2 may rather suppress the increased vascular permeability elicited by histamine,
bradykinin, and C3a, thus preventing inflammatory reaction (Yoshikai, 2001).
In dermai inflammation, application of PGE2 or PGI2 alone increases blood
flow, but does not promote oedema. However, co-injection of either agent with
chemotactic mediators such as LTB4, IL-8, PAF-ci or bradykinin causes profound
plasma protein leakage (Wedmore and Wiiliams, 1981). PGs also moduiate leukocyte
function. For instance, PGE2, PGD2 and PGI2 ail inhibit PMN activation in vitro, as
measured by chemotaxis and superoxide production (Wheeldon and Vardey, 1993).
The inhibitory effect is associated with increase in cAMP formation. PGE2 is also a
potent inhibitor of monocyte activation as it inhibits TNF production in vitro. In vivo,
administration of COX-inhibitors enhances the release of TNF-ci in response to
administration ofLPS (Pettipher and Wimberly, 1994).
In addition, PGs may reguiate lymphocyte function via modulation ofthe EP2
and EP4 receptor expression during acute inflammation (Griffiths, 1999). For
example, PGE2 inhibits T-cell proliferation, cytokine production, and T-celi
migration through a cAMP-mediated mechanism, invoiving EP2 or EP4 receptors.
1.3.4.3. Leukotrienes
The term “leukotriene” (Lis) refers to the ceilular source (leukocytes are one
of the ma] or sources) as well as the con] ugated triene that characterizes their structure
(Samueisson et al., 1979). Leukotrienes are formed from the catalytic oxygenation of
20-carbon unsaturated fatty acids, mainly arachidonic acid. Leukotrienes can be
divided into two different classes, based upon their chemical structure and biological
activity;
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Ihe cysteinyl leukotrienes (CysLTs), namely LTC4, LTD4, and LIE4,
containing different amino acid residues
The dihydroxy-derivative leukotriene B4 (LIB4)
Briefly, CysLTs were originally described as the slow reacting substance of
anaphylaxis (SRS-A) because of its slow and sustained smooth muscle contracting
abilities. LTB4 (5 S, 1 2R-dihydroxy-6, 1 4-cis-8, 1 0-trans-eicosatetraenoic acid) was
isolated and purified in 197$ from neutrophils upon activation by calcium ionophores
such as A23 187 (Borgeat and Samueisson, 1979a), and characterized as a major AA
metabolite in rabbit polymorphonuclear leukocytes (Borgeat and Samueisson,
Ï 979b).
1.3.4.3.1. Leukotriene biosynthesis in leukocytes
Ihe limiting step in the generation of Lis is the enzymatic release of AA
from the ceil membrane phospholipids by PLA2. The first committed step in Lis
formation from AA is through the enzymatic action of 5-lipoxygenase (5-LO) that
requires ceil activation and influx of intracellular and extracellular calcium (Wong et
al., 1991). Stimulation of neutrophils resuits in the transiocation of 5-LO, a cytosolic
or nuclear soluble enzyme, to the nuclear envelope where it colocalizes with the 5-
lipoxygenase activating protein (FLAP). FLAP is an integral membrane protein
necessary for leukotriene synthesis, initially thought to act as a docking protein for 5-
LO. Its role appears to be more complex, and may include efficient conversion ofAA
to leukotrienes by handing the substrate to 5-LO (Abramovitz et al., 1993).
5-LO catalyzes the insertion of reactive oxygen into arachidonic acid at C-5
leading to formation of 5-hydroperoxyeicosatetranoic acid (5-HPETE). ihis unstable
lipid hydroperoxide may be either reduced by peroxidase to the hydroxy metabolite
(5-HETE) or can be stereospecifically dehydrated by a second 5-LO catalyzed step to
eicosatetraenoic acid (LIA4) (figure 1.6) (Sirois and Borgeat, 1988). LiA4
undergoes transformation by one or more metabolic pathways depending on the
cellular context; hydrolysis ofLiA4 by the LIA4 hydrolase occurs in the cytoplasm,
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and potentially in the nucleus, yielding LTB4. a potent neutrophil chemoattractant
(Peters-Golden and Brock, 2001). LTA4 conjugation with glutathione at the nuclear
envelope yield LIC4, a step catalyzed by LIC4 synthase. LIC4 can be metabolized by
a ‘y-glutamyltransferase to LTD4. a cysteinyl-glycyl conjugate that in mm can be
ffirther metabolized by ubiquitous peptidases to the cysteinyl containing LIE4.
Neutrophils have been shown to synthesize large amounts of LIB4,
possessing 5-LO and LIA4 hydrolase, whereas eosinophils and mast ceils
preferentially synthesize LIC4, according to the presence of 5-LO and LIC4 synthase
within these celis. However, the co-incubation of different celi types was shown to
greatly influence, both the quantitative and the qualitative profile of the leukotrienes
produced (Maclouf and Murphy, 1988). These changes were shown to depend on the
ability of neutrophils to export the unstable intermediate LTA4 to neighboring ceils,
which may flot have the primary oxidative enzyme, namely the 5-LO, but possess
either LTA4 hydrolase (erythrocytes) or LIC4 synthase (platelets, endothelial celis
and vascular smooth muscle ceils).
1.3.4.3.2. Leukotriene receptors and signaling pathways
Leukotrienes act at distinct celi surface G protein-coupled feceptors; the
receptors for LIB4 are called BLT receptors and the CysLTs receptors are designated
CysLI receptors. BLT receptors are higffly expressed in human leukocytes (Goldman
and Goetzl, 1984). In neutrophils, two BLI receptors subtypes have been identified.
Indeed, Yokomizo et al. (2000) identified the second leukotriene B4 receptor, BLI2,
ftom humans and mice and found that the BLI2 gene closely located to the BLI1
gene in both humans and mice. In addition, the BLT1 receptor may show two
different affinity states which have been linked to different functional responses. The
high-affinity receptor state BLI1) transduces the functions of chemotaxis and
adhesion, whereas the low-affinity receptor state mediates the secretion of granule
content and superoxide generation. In addition, LIB4 binds to a nuclear receptor,
PPAR-Œ (peroxisome proliferator-activated receptor-a), which enhances the
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Figure 1.6 . Metabolism of arachidonic acid by 5-LO enzyme and biosynthesis of
leukotrienes
from Sirois and Borgeat, 1988.
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and potentially in the nucleus, yielding LTB4, a potent neutrophil chemoattractant
(Peters-Golden and Brock, 2001). LTA4 conjugation with glutathione at the nuclear
envelope yield LTC4, a step catalyzed by LTC4 synthase. LIC4 can be metabolized by
a ‘y-glutamyltransferase to LTD4, a cysteinyl-glycyl conjugate that in turn can be
further metabolized by ubiquitous peptidases to the cysteinyl containing LIE4.
Neutrophils have been shown to synthesize large amounts of LTB4,
possessing 5-LO and LTA4 hydrolase, whereas eosinophils and mast ceils
preferentially synthesize LIC4, according to the presence of 5-LO and LIC4 synthase
within these celis. However, the co-incubation of different celi types was shown to
greatly influence, both, the quantitative and the qualitative profile ofthe leukotrienes
produced (Maclouf and Murphy, 198$). Ihese changes were shown to depend on the
ability of neutrophils to export the unstable intermediate LIA4 to neighboring celis,
which may not have the primary oxidative enzyme, namely the 5-LO, but possess
either LTA4 hydrolase (erythrocytes) or LIC4 synthase (platelets, endothelial ceils
and vascular srnooth muscle ceils).
1.3.4.3.2. Leukotriene receptors and signaling pathways
Leukotrienes act at distinct ceil surface G protein-coupled receptors, the
receptors for LTB4 are called DLI receptors and the CysLIs receptors are designated
CysLT receptors. BLT receptors are highly expressed in human leukocytes (Goidman
and Goetzl, 1984). In neutrophils, two DLI receptors subtypes have been identified.
Indeed, Yokomizo et al. (2000) identified the second leukotriene B4 receptor, BLI2,
ftom humans and mice and found that the BLI2 gene closely located to the BLT1
gene in both humans and mice. Ihe BLI receptors are member of G protein-coupled
receptor, the high-affinity receptor (BLT1) mediates aggregation, chemotaxis,
chemokinesis. and increased adherence to surfaces, whereas the low-affinity receptor
(BLT2) mediates degranulation and increased oxidative metabolism. In addition,
LTD4 binds to a nuclear receptor, PPAR-Œ (peroxisome proliferator-activated
receptor-Œ), which enhances the transcription of enzymes jnvolved in LTB
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inactivation and plays a role in LTB4 clearance during inflammation (Devchand et al.,
1996).
On the basis of primarily functional studies in smooth muscle, the CysLTs
receptors are dïvided into two subtypes; CysLT1 mediates the action of LTD4 and
LTE4, whereas CysLT2 interacts with LIC4 (Penrose et al., 1999).
Binding of leukotrienes to its receptors induce intracellular signaling by
activation of PLC leading to production of inositol triphosphate (1P3) and
diacyglycerol (DAG) from the plasma membrane. 1P3 causes the release of Ca2 from
the endoplasmic reticulum and produces 1P4 which resuits in Ca2 influx from the
extracellular space. DAG, together with intracellular Ca2, results in the activation of
protein kinase C (PKC) which plays an important role in the activation of neutrophils,
macrophages, and lymphocytes (Bulger and Maier, 2000).
LTB4 receptors undergo homologous desensitization, a control mechanism
that potentially limits its signaling actions. Continuous exposure of circulating PMNs
to a steady-state concentration of LTB4 resulted in a homologous desensitization to
LTB4-induced neutropenia (Sirois et ai, 1983, Marleau et al., 1993).
1.3.4.3.3. Role of leukotrienes in inflammation
1.3.4.3.3.1. Pathophysiological effects
LTB4 stimulates neutrophil chemokinesis and chemotaxis, enhances
neutrophil-endothelial interaction, and stimulates neutrophul activation, leading to
degranulation and release of inflammatory mediators including PAF and LTB4 itse1f
lysosomal enzymes and superoxide (PaÏmblad et al., 1981). LTB4 also stimulates IL-6
production by human monocytes as weÏl as the production of other cytokines such as
GM-CSf, IL-1 and TNF (Brach et al., 1992; Stankova and Rola-Pleszczynski, 1992).
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The chemotactic activity ofLTB4 has been shown in vivo following injection
in rat peritoneal cavity, resulting in substantial accumulation of macrophages and
PMNs (Smith et al., 1980). Intradennal application of LTB4 or injection into the
interior chamber of rabbit eye showed accumulation of PMNs at the site of injection
(O’Flaherty et al., 1981). Intratracheal instillation of LTB4 in humans increased the
total number of neutrophils recovered by bronchoalveolar lavage (BAL) (Martin et
al., 1989).
In vivo, LTB4 has the potential to increase vascular permeability, possibly as a
resuit of PMNs activation (Bray et al., 1981; Bjork et al., 1982). In vitro, LTB4
increases 5-LO activation in human PMNs in an autocrine fashion (McDonald et al.,
1994).
The CysLTs are involved in the regulation of vascular tone and permeability.
The intratracheal administration of LIC4 and LTD4 results in a significant increase in
pulmonary capillary permeability leading to pulmonary oedema (Woodward et al.,
1983).
1.3.4.3.3.2. Identification of leukotrienes at lesional sites
Leukotrienes are present in the biologic fluids of inflammatory lesions in
several disease states. LTB4 is found in the rectal fluid of patients with inflammatory
bowel disease, the skin lesions of patients with psoriasis, and in the synovial fluid of
patient with rheumatoid arthritis (Davidson et al., 1983; Tsuji et al., 1999) and gout
(Rae et al., 1982; Penrose et al., 1999). In patients with rheumatoid arthritis, the
elevated levels of LTB4 in the synovial fluid correlate with the increase number of
synovial fluid leukocytes, immune complexes, and rheumatoid factor (Ahmadzadeh
et al., 1991). CysLTs are present in serum, bronchial lavage fluid, and urine of
patients with bronchial asthma (Wardlaw et al., 1989) and others diseases including
allergic rhinitis and conjunctivitis (Bisgaard et al., 1985).
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Supporting a foie of Lis in clinicai inflammatory conditions, 5-LO inhibitors
improved symptoms in many disease disorders such as ulcerative colitis, psoriasis
(Black et al., 1990), and asthma (Israel et al., 1993).
1.3.4.4. Platelet-activating factor
1-O-alkyi-2-acetyl-.sn-glycero-3-phosphocholine (PAF) is a potent mediator
produced by a number of inflammatory celis including piatelets, PMNs,
macrophages, ECs and epithelial ceils, which present specific receptors for PAF,
functioning in both a paracrine and autocrine fashion. As with eicosanoids, PAF is
synthesized when inflammatory ceils are activated, and its synthesis and subsequent
secretion are closely reguiated. For example, PAF, as LTB4, is synthesized in large
amounts upon activation ofPMNs by calcium ionophores (A23 187) or by phagocytic
stimuli such as zymosan or inflammatory microcrystals (Borgeat and $amuelsson,
1979a; Riches et al., 1990; McDonald et al., 1994).
1.3.4.4.1. Platelet-activating factor synthesis in leu kocytes
PAF may be synthesized through either the rernodeling or de novo enzymatic
pathways (figure 1.7). PAF synthesis through the remodeling pathway is initiated by
activation of a cPLA2 enzyme that hydrolyzes 1-O-alkyl-2-acyl-sn-glycero-3-
phosphocholine to 1 -O-alkyl-2-lyso-sn-giycero-3 -phosphocholine (lyso-PAF) and
arachidonate. The remodeling pathway appears to be the principle mechanism of the
synthesis of PAF in stimulated neutrophils, monocytes and ECs in various
inflammatory and allergic disorders. The second and final step is the acetylation of
lyso-PAF by acetyl-CoA:lyso-PAF acetyltransferase (lyso-PAF AcT) to form PAF.
This step is also reguiated since lyso-PAF AcT is activated by phosphorylation
(PepÏow, 1999; Prescott et ai., 1999). The formation of PAF via the remodeling
pathway is always accompanied by the release of arachidonic acid that can be
converted into a variety ofpotent bioactive eicosanoid mediators.
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Figure 1.7 Pathways of platelet-activating factor biosynthesis
From Prescott et al., Platelet-activating factor. In Inflammation: Basic
Principte and Clinical Corretate 3rd ed, 1999.
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The second mechanism of PAF synthesis, de novo pathway, starts with 1-O-
aÏkyl-sn-glycero-3-phosphate which is acetylated by the alkylglycerophosphate acetyl
transferase enzyme, followed by removal of the phosphate by a phosphohydrolase
enzyme and its replacement with phosphocholine, the last reaction catalyzed by PAF
phosphocholine transferase (PAF-PCT) (Peplow, 1999). The enzymes in this pathway
are constitutively active and regulated by the availability of substrate.
PAF synthesized via the remodeling pathway is secreted into the fluid phase
by human monocytes and eosinophils. In contrast, PAF synthesized by endothelial
celis via the same pathway is translocated to the plasma membrane and retained on
the celi surface.
Degradation of PAF occurs by hydrolysis of the sn-acetyl residue to generate
lyso-PAF and acetate. This reaction is catalyzed by PAF acetylhydrolase (PAF-AH)
(figure 1.$). PAF-AH belongs to group VI ofPLA2.
1.3.4.4.2. Platelet-activating factor receptors
The action of PAF is mediated tbrough a member of G protein-coupled
receptors. The receptors from several species have been cloned and characterized at
the molecular level. PAF acts by binding to a specific receptor (PAFR) which is a “7-
membrane-spanning” receptor and induces intracellular signaling via PLC-
activation and turnover of phosphatidylinositol. As consequence, there is an increase
in intracellular calcium and activation ofPKC (Peplow, 1999).
PAFR undergoes homologous desensitization, a control mechanism that
potentially limits its signaling actions. Desensitization of the PAFR is accompanied
by phosphorylation of the PAF receptor (Takano et al., 1994; Mi et al., 1994). In
summary, PAFR can be desensitized in multiple ways. Homologous desensitization
ofPAFR uses two mechanisms: phosphoiylation ofthe receptor (probably by a G-
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protein-coupled receptor kinase-1, GRK) and inactivation of the key downstream
effector PLC-f33 by PKC. Heterologous desensitization of the PAFR uses a third
mechanism: phosphorylation ofthe receptor by PKC (Prescott et al., 2000).
1.3.4.4.3. Rote of PAF in inflammation
PAF has been implicated in the pathogenesis of both acute inflammation and
hypersensitivity disorders. PAF is a potent activator of human neutrophils and
stimulate neutrophil adhesion, lysosomal enzyme release, generation of reactive
oxygen species and eicosanoids (Smith et aÏ., 1984). In inflammation, rapid activation
of ECs change their surface properties to become adhesive for leukocytes, with P
selectin expression facilitating leukocyte tethering (Mayadas et aÏ., 1993). The
leukocytes that have been tethered are then activated by PAF, which is produced and
displayed on the ECs surface (Zimmerman et al., 1992). The in vitro demonstration
that P-selectin and PAF cooperatively mediate the adhesion of PMNs to the activated
ECs is supported by in vivo studies showing that antibodies to P-selectin and PAF
receptor antagonists suppress the inflammation (Coughlan et al., 1994).
PAF can activate human monocyte ceils by increasing the synthesis of
chemokines, cytokines, tissue factor, and other mediators (Zimmerman et al., 2002).
Thus PAF stimulates the release of several cytokines including IL-1 and TNF,
resulting in significant amplification ofthe inflammatory process.
In vivo, PAF was shown to trigger aggregation and accumulation of platelets
and to induce subsequent changes in local blood flow at the site of experimental
thrombosis and vascular injury (Golino et al., 1993). Platelets aggregation is mediated
by inside-out signaling of the integrin Œ1Ib33 and consequent binding of fibrinogen
(Shattil et al., 1998), indicating that the PAF receptor is linked to this prothrombotic
intracellular pathway.
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Work from a variety of sources has suggested that PAF is a mediator of
sepsis. For example, PAF antagonists block endotoxin-induced recmitment of
platelets to the lung (Beijer et al., 1987). PAF is also involved in inflammatory bowel
disease and its inhibition by specific antagonists may have a potential therapeutic
benefit in treatment ofthese inflammatory diseases (Nassif et al., 1996).
PAF could be implicated in the pathogenesis of chronic arthritis considering
that PAF antagonists have beneficial effects in a model ofjoint injury (Palacios et al.,
1999). Other investigators found PAF in bronchoalveolar lavage (BAL) fluid from
ARDS patients (Matsumoto et al., 1992). In addition, clinical trial have suggested that
PAF receptor antagonist may be beneficial in treating pancreatitis (Kingsnorth et al.,
1995).
1.4. Aims of the present research project
Experimental evidence suggests that lipid mediators play an important role in
regulating PMN extravasation at the blood endothelium interface by regulating, for
instance, vascular permeability, vasodilation, and/or endothelial celi
hyperadhesiveness for neutrophils (Marleau et al., 1999).
The goal of the present study is to delineate the role of PAF and LTB4 in
neutrophil trafficking in a model of dermal inflammation in rats. The local injection
of certain lipid mediators, including LTB4 and PAF in the dorsal skin of male
Sprague-Dawley rats, stimulates PMNs and/or ECs to facilitate the transmigration
process of PMNs. In addition, LTD4, by causing ECs retraction may also contribute
to PMNs extravasation. In order to delineate the role ofthese lipid mediators and their
potentially synergistic or additive effects on leukocyte migration, we have used
selective LTB4 and PAF receptor antagonists in a dermal inflammatoiy model.
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Briefly, rats were pretreated with either a LTB4 andlor PAF receptor
antagonist afler which neutrophil accumulation was elicited by intradermal agonist
injections. The mediators under study included LTB4, PAF, TNF-Œ, IL-8 and ZAP.
PMN accumulation to skin sites has been assessed by the myeloperoxidase (IVWO)
assay. In additional studies, we have assessed the role of lipid mediators on plasma
extravasation and microcirculatory blood flow using the same compounds. The dmg
used included the selective LTB4 receptor antagonist (CP-105,696) and selective PAF
receptor antagonists (UK-74,505 and SR-27417).
Hence, this research project enabled us to ffirther delineate the role of lipid
mediators in leukocyte trafficking by elucidating;
1. The role of LTB4 in PMN emigration, plasma extravasation and
microcirculatory changes in blood flow elicited by PAF or other soluble
agonists (ZAP, IL-8 and TNF-Œ);
2. The role of PAF in PIvN emigration, plasma extravasation and
microcirculatory changes in blood flow elicited by LTB4 or other soluble
agonists (ZAP, IL-8 and TNF-Œ);
3. The potentially synergistic or additive effects of lipid mediators, including
LTB4, PAF and LTD4 in PMN emigration, plasma extravasation and
microcirculatoiy changes in blood flow elicited by soluble agonists
including PAF, LTB4 and other soluble agonists.
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2.1. Chemicals
Neupogen° (filgrastim) was obtained from Amgen Canada Inc.
(Mississauga, Ontario). Bovine semm albumin (BSA) (10w endotoxin), casein,
dimethyl suiphoxide (DMSO), hexadecyltrimethylammonium bromide (HTAB),
hydrogen peroxide (H202), N,N-dimethylformamide (DMF) 99.9%, PAF, substance
P, 3,3’,5,5’-tetramethylbenzidine (TMB) and zymosan were purchased from Sigma
Aldrich Company (St. Louis. MO). LTB4, LTD4 ami PGE2 were purchased from
Cayman Chemical (Homby, Ontario, Canada). Evans Blue was obtained from Fisher
Scientific Company (fair Lown, New Jersey). Dextran T-500 and Percoil were
obtained from Pharmacia Canada Inc. (Baie d’Urfé, Qc, Canada), and modified
Hank’s Baianced Sait Solution (HBS$) and HEPES buffer were from Gibco Life
Technologies (Grand Island, NY). Human recombinant (hr) IL-8 and hrTNF-Œ were
purchased from PeproTech, Inc. (Rocky Hill, NJ, USA). UK-74,505 (4-(2-
cfflorophenyl)-1 ,4-dihydro-3 -ethoxycarbonyl-6-methyl-2-[4-(2-methylimidazo[4,5-
c]pyrid- 1 -yI)phenyll-5-[N-(2-pyridyl)carbamoyl]pyridine) and (+)- 1 -(3 S,4R,)—[3 -(4-
phenyi-benzyl)-4-hydroxy-chroman-7-yi]-cyclopentan carboxylic acid (CP- 105,696)
were kind gifis from Pfizer Central Research (Sandwich, Kent, UK) and (Groton,
USA), respectiveiy. SR-274 17 [N-(2-dimethylamino-ethyl)-N-(3-pyridinylmethyi)[4-
(2,4,6-triisopropyl-phenyl)thiazol-2-yiJaminel was a kind gifi from Sanofi Recherche
(Toulouse, France). Solutions for parenteral administration, such as the Evans blue
solution, were made from pyrogen-free, sterile 0.9% NaCl (Baxter Corporation
Laboratories, Toronto, Ontario, Canada).
2.2. Animais
Maie Sprague-Dawiey rats (90-100g) were purchased from Charles River (St
Constant, Québec, Canada). They were maintained in cages with ftee food and water
for 9-11 days before doing any experimentai work. During this period of time, fats
were injected subcutaneously (s.c.) with 5 jig/kg G-CSF (Neupogen) diluted with
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0.9% NaC1. Neupogen was injected until the day of the experiment in order to
increase the number of circulating PMN in the rats, resulting in a proportional
increase in the local accumulation of PMN in response to agonist challenge. The
increased PMN numbers at local sites facilitated assessment of the effect of drugs on
agonist-induced PMN accumulation in a quantitative manner.
2.3. Isolation and purification of rat peritoneal neutrophuls
Rat PMNs were obtained by a modification of the method described by
Bokoch and Gilman (1984). Animais were injected intraperitoneally (i.p.) with 10 ml
of 5% sodium casemate. The peritoneal exudates were coilected 6 h later in 30 ml
heparinized saline (10 units/ml). Neutrophils were purified using a Percoil gradient,
the neutrophil ricli band was collected and contaminating red blood celis (RBC)
removed by hypotonic lysis. The purified neutrophils were greater than 98% pure,
contaminating celis being mononuclear ceils. The ceil suspension was diluted to 0.5 x
106 PIVIN/ml with acetate buffer containing 0.5% HTAB, aliquoted and kept at -20°C
untii assayed for myeloperoxidase (MPO) activity in a PMN standard curve.
2.4. Preparafion of zymosan-activated plasma (ZAP)
ZAP, a source of C5auesg, was prepared by incubating heparinized (10
units/ml) rat plasma with zymosan (5 mg!ml) for 30 min at 37°C. Zymosan was
removed by centriffigation (2 x 10 min at 3000 g) and ZAP was stored in aiiquots at
-20°C.
2.5. Experimental protocol
The drugs (PAF and LTB4 antagonists) were dissolved in appropriate vehicles
and administered to the rats orally at specific times before the intradermal (id.)
injections of agonists. CP-105,696 was dissolved in 0.5% carboxymethyl cellulose
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(CMC) and administered 16 h prior to i.d. agonist injections. UK-74,505 was
dissolved in 0. iN HCÏ, diluted with sterile water and administered 2 h prior to i.d.
agonist injections. SR-274 17 was dissolved in sterile water and administered 2 h prior
to i.d. agonist injections. Control rats received an oral administration of vehicle.
Rats were sedated by a s.c. injection of Hypnorm (fentanyl-fluanisone,
Janssen Pharmaceutica, Beerse, Belgium) (0.15 ml), the dorsal skin of the rats was
shaved, and the sedated animais were placed on heating pads.
2.5.1. Agonist preparation
The agonists under investigation, LTB4, PAF, IL-8, TNF-Œ, LTD4 and
substance P, were dissolved as followed:
• LTB4, PAF, PGE2 and LTD4 were initially dissolved in ethyl alcohol and
diiuted with 0.1% HBSS/BSA (final % ofsolvent is <0.1%).
• IL-8 (25 jig) and TNF-a. (50 fig) were dissolved in sterile water and
Substance P in sterile 0.9% NaC1 before diluting with 0.1% HBSS/BSA.
• ZAP, prepared as described above, was diluted in 0.1% HBSSfBSA and
used at concentrations of 3 and 30%.
Ail agonists were co-injected with 250 pmol PGE2, a potent vasodilator, to
enhance PIvN extravasation and facilitate measurements ofMPO activity.
2.5.2. Measurement ofPMN accumulation in rat skin
PMN accumulation in response to i.d. injected agonists was quantified by
measuring MPO activity in skin biopsies. The agonists, freshly prepared from stock
solutions, were injected i.d. (50 t1 per site) at duplicate sites in the dorsal skin of the
rat (figure 2.1) according to a well-balanced and randomized site injection plan. The
agonists under study included LTB4 (500 pmollsite), PAF (1.9 nmollsite), ZAP (3 and
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Figure 2.1. Intradermal injections ofagonists in the rat dorsal skin
Figure 2.2. Punching ofthe skin biopsies
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30%), IL-8 (50 pmollsite), TNF-Œ (50 pmoWsite) and vehicle (BBS$IB$A 0.1%).
Afler a 2 h period to allow PMN accumulation, the rats were anaesthetized with a
solution of ketamine (Vetrephann-Canada Inc. Belleville, ON) (90 mg/kg) and
xylazine (Bimeda-MTC Animal Health Inc. Cambridge, ON) (10 mg/kg); a mid-line
incision was performed on the thorax and 1 ml of blood was taken from the thoracic
aorta to determine total and differential leukocyte counts. The rats were sacrificed
with an overdose of pentobarbital (Euthanyl, Schering Canada Inc. Pointe-Claire,
Québec) injected directly into the heart, and the dorsal skin was harvested and
cleaned of excess blood and fat. The skin biopsies were punched out (11 diam. i.d.)
(Figure 2.2), weighed, and frozen at -80°C until assayed for MPO activity.
2.5.2.1. MPO enzymatic assay
The MPO assay was performed by a modification ofthe method described by
Stark et al. (1992). Briefly, the biopsies were thawed and homogenized in 100 mM of
acetate buffer pH 6, containing 0.5% HTAB and 20 mM EDTA. The homogenates
were sonicated on ice for 15 s, frozen (-80°C), subjected to three fteeze-thaw cycles,
and then centrifuged (15°C, 2000 X g for 15 mm). The supematants are flltered and
diluted with the acetate buffer solution. A 3.2 mM stock solution (10 jil) ofTlVffi (in
DMSO) was added to 75 j;! of the ifitrate, and the solutions were preincubated at
37°C for 5 min. The enzymatic reaction was started by the addition of 50 pi of a
solution of 1.0 mM H202 in 0.2 M acetate buffer pH 6, and incubated at 37°C for 5
min. The reaction was terminated by the addition of 100 1.11 of 0.2 M sodium acetate
(pH 3.0). The absorbance of the samples was determined at 630 nm and the number
of PMN per site was calculated according to a standard curve from rat PMN obtained
from the peritoneal cavity. The resuits are expressed as PMN/site.
2.5.3. Measurement of locat oedema formation in rat skin
The extravasation of Evans blue dye into the tissue was used as an index of
increased vascular permeability and oedema formation. The procedure of measuring
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local oedema was identical to that of PMN accumulation except for the following:
Evans blue (lOOmg/kg) solution in sterile 0.9% NaC1 (10% wlv) was injected i.v. in
the jugular vein. Five minutes later, the agents under study, fteshly prepared in
HBSS/B$A 0.1%, were injected i.d. (50 .tl per site). The agonists included PAF (1.9
nmollsite), LTD4 (500 pmollsite), substance P (100 pmollsite) and vehicle
(HBSS/BSA 0.1%). The animais were sacrificed 30 min afler the i.d. injections. A
blood sample (1 ml) was obtained immediately prior to sacrifice and plasma was
prepared by centrifugation (3000 X g, 10 mm) and kept at -20°C until assayed for
Evans blue. The dorsal skin was subsequently removed and the injected sites were
punched out (11 diam. i.d.).
2.5.3.1. Evans blue assay
Evans blue was extracted by incubating the minced skin sites in 0.25 ml DMF
at room temperature for 48 h and quantified by measuring the absorbance at 630 nm.
Evans blue in the plasma was quantified, following dilution with water, by measuring
the absorbance at the same wavelength. The concentration of Evans blue in skin site
and plasma was determined using a standard curve of Evans blue. Plasma
extravasation in the skin was expressed in terms of pi of plasma, and calculated by
dividing the concentration of Evans blue in the skin site per its concentration in 1 tl
of plasma.
2.5.4. Measurement ofthe microcirculatory blood flow in rat skin
The day before the experiment, rats were sedated by injecting Hypnorm (0.15
ml) s.c. and the dorsal region ofthe rats was shaved carefully to remove the hair. The
experimental protocol started by inducing rat anaesthesia with an i.p. injection of a
Ketamine/Xylazine (90:10) solution (0.1 ml).
Skin blood flow was measured noninvasively with a laser-doppler blood
flowmetry (Periflux system 5000) (figure 2.3). Using this technique, basal
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mjcrovascular blood flow of ail skin sites was measured and only those with similar
basal flow were used for intradennal injections. The area of measurement was 1 mm2
and the depth of the laser beam penetration was approximately 0.5-1.5 mm. The
agonists under investigation included PAF (3.8 nmollsite), LTB4 (1000 pmollsite) and
vehicle (IBSS/BSA 0.1%). The local microvascular blood flow was recorded before
injection of the agonists, and again foliowing i.d. injections of 100 t1 of freshly
prepared agonists, incubated at 37°C for 1 min before injection. The optic fibre probe
was placed about 2 mm from the circumference ofthe injection site delineated with a
color marker, and changes in the local microvascular blood flow responses were
measured directly afier agonist injections and monitored for 5 minutes.
Resuits are shown as representative tracing of the vasodilator responses to
various agonists in control rats and in rats treated with the PAF antagonist (SR
27417). The rats were allowed to recover and were used again after at least one week
ofwashout period before another blood flow experiment.
2.6. Statistical analysis
Ml results are expressed as mean ± SEM. Statistical significance was assessed
by a one-way ANOVA with Student-Newman-Keuls for multiple comparisons as a
post-test, using GraphPad InStat version 3.05 Software (San Diego, Califomia, USA).
P values <005 were considered statistically significant.
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Figure 2.3. Laser-doppler apparatus
Periflux system 5000 (Perimed AB, Stockholm, Sweden)
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3.1. Preliminary experiments
3.1.1. Dose-dependent effect of a LTB4 antagonist on LTB4-induced
PMN accumulation in rat skin
Prior studies in our laboratory have shown a dose-dependent inhibition of
LTB4 Ïnduced PMN accumulation by a selective LTB4 antagonist, CP-105,696. The
doses of 10 and 30 mg/kg significantly reduced PMN accumulation, induced by LTB4
(500 pmoL’site), by 43 % and 77 % respectively (figure 3.1).
3.1.2. Dose-dependent effect of selective PAF antagonists, on PAF
induced PMN accumulation in rat skin
Preliminaiy experiments were perfonrted to assess the dose-dependent
inhibition ofthe selective PAF antagonist UK-74,505. UK-74,505, administered at a
dose of 2.5 mglkg, tended to reduce PAF-elicited PMN accumulation by 28%, while
a dose of 5 mglkg was found to inhibit PIVIN accumulation by 61% (F < 0.05) (figure
3.2).
Similar studies were performed to determine the optimal dose of SR-27417, a
potent and selective PAF receptor antagonist. As shown in figure 3.3, SR-27417, at a
dose of 0.1 mg/kg, did flot significantly reduce PIVIN accumulation (16%, F> 0.05),
but optimally inhibited PMN accumulation induced by PAF at a dose of 1 mg/kg by
65% (P < 0.05).
In both ofthese preliminary experiments, the dose ofthe intradermal agonist
PAF was of 950 pmollsite. In addition, no PGE2 was used as vasodilating agent.
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Figure 3.1. Dose-dependent inhibition of LTB4-elicited PMN accumulation by pretreatment
of rats with CP-105,696.
Data represent the mean ± SEM of $ sites obtained from 4 rats.
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Figure 3.3. Dose-dependent inhibition of PAF-elicited PMN accumulation by pretreatment
of rats with SR-27417.
Data represent the mean ± SEM of 4-8 sites obtamed ftom 2-4 rats.
According to the resuits of these preliminary experiments, we conducted
subsequent studies using the selective PAF receptor antagomsts 11K-74,505 at a dose
of 5mg/kg and SR-27417 at a dose of lmg/kg. The selective LTB4 receptor antagonist
CP-105,696 was used at doses of lOmg/kg and 3omglkg.
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3.2. Effects of PAF and LTB4 antagonists on PMN accumulation
elicited by a vanety of chemoaftractant agonists
To delineate the role of PAF and LTB4 in the inflammatory response induced
by PAF and LTB4, we have used selective and long-acting PAF antagonists (UK
74,505 and SR-27417) and a patent and long-acting LTB4 antagonist CP-105,696. A
second chemically unrelated LTB4 antagonist such as LY 293111 or BIIL 284 was
unavailable in sufficient quantities for in vivo administration in rats at the time of
study.
Resuits are presented as a percentage of PIvIN accumulation compared to the
vehicle-treated group. The (n) number is specified in figure legends.
3.2.1. Effect ofUK-74,505 andlor CP-105,696 on inflammatory
mediator-induced PMN accumulation in rat skin
Experiments were undertaken to study the effect ofUK-74,505 at a dose of 5
mglkg and!or CP-105,696 at a dose of 30 mglkg on PIVJN accumulation induced by
PAF (1.9 nmol!site, a dose higher than tested previously but giving more reproducible
PIVIN accumulation) and LTB4 (500 pmollsite). PMN accumulation, in vehicle-treated
rats, elicited by PAF (1.9 nmol) was 47812 ± $105 PMN per site and 157955 ± 28385
PMN per site when LTB4 (500 pmol) was used as an i.d. agonist. UK-74,505
significantly reduced PAF-induced PMN accumulation by 51% (F < 0.05), whereas
CP-105,969 tended to reduce PMN numbers in the skin (38%, F > 0.05) (figure
3.4A). When CP-105,696 and UK-74,505 were co-administered, an additive
inhibitory effect on PAF-elicited PMN accumulation (73%, F < 0.01) was observed.
In contrast, while CP-105,696 potently reduced PMN accumulation induced
by LTB4 (79%, F < 0.001), UK-74,505 tended to reduce LTB4-elicited PMN
accumulation (39%, P > 0.05). When both antagonists were administered to the rats,
no additive inhibitory on LTB4-elicited PMN accumulation was observed (78%, F <
0.001) (figure 3.4B).
Chapter 3: Results 56
w
w•t5
Q,
4-
E
o
C
4-.-
. .c
I-C
C
a-o
4-
z.
Q-.
___ ___
E
o
o
Figure 3.4. Effect ofUK-74,505 and/or CP-105,696 on PAF-elicited PN’fN accumulation (A)
& LTB4-elicited PMN accumulation (B) in rat dorsal skin
Data represent the mean ± SEM of 8-12 sites obtamed from 4-6 rats.
PAF (1.9 nmollsïte)
+ PGE2 (250 pmol/site)
A
100
80
60
40-
20-
liii VEHICLE
UK74,505 (5mg/kg)
CPi 05,696 (3omglkg)
UK74,505 (5mglkg)+
CPi 05,696 (3Omg/kg)
LZJ VEHICLE
EZI UK74, 505 (5mg/kg)
CP1O5,696 (3omglkg)
EEEI UK74, 505 (5mglkg)+
CPI 05,696 f3Omg/kg)
LTB4 (500 pmol/site)
+ PGE2 (250 pmol/site)
T
B
100-
80-
60
40
20
O
***
r”..’
\
Chapter 3: Resutts 57
3.2.2. Effect of SR-27417 and/or CP-105,696 on inflammatory
mediator-induced PMN accumulation in rat skin
For these studies, we initially used SR-27417 at a dose of 1 mg/kg which,
according to our preliminary experiments, was shown to inhibit PAF-induced PMN
accumulation in rat skin by 65%. However, we have found that this dose inhibited the
effect ofPAF by 94 % in subsequent experiments; it may be partly due to the fact that
we undertook studies in slightly lower weight rats (100 vs 125 gm) in addition of
using a new batch of the dmg. Hence, subsequent studies were done using a 0.3
mglkg dose ofSR-27417.
The first series of experiments were done using of SR-2741 7 at a dose of 1
mg/kg and/or CP-105,696 at a dose of 10 mg/kg as a pretreatment in rats locally
injected with LIE4 (500 pmollsite) and PAF (1.9 nmol/site).
Our resuits show that SR-27417 (1 mglkg) inhibited PAF-elicited PMN
accumulation by 94% (P < 0.01) whereas CP-105,696, at dose of 10 mg/kg, tended to
reduce the PAF-induced PMN accumulation by 54% (P> 0.05) (figure 3.5A). When
bath drugs are co-administered, the PMN accumulation induced by PAF was
inhibited by 96% (P < 0.001) (figure 3.5A)
When LTB4 was used as an i.d. agonist, we observed that CP-105,696
significantly inhibited PMN accumulation (84%, P < 0.00]) (figure 3.5B). In
contrast, SR-27417 did flot affect the LTB4-induced PIVIN accumulation. When SR
27417 was administered together with CP-105,696, PIVIN accumulation was reduced
by 90% (F < 0.01) (figure 3.5B).
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figure 3.5. Effcct of SR-27417 (1 mglkg) andJor CP-105,696 (10 mg/kg) on PAf-clicited
PMN accumulation (A) & LTB4-elicited PMN accumulation (B) in rat dorsal
skin
Data represent the mean ± SEM of 8-12 sites obtamed from 4-6 rats.
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In another series of experiments, we studied the effect of SR-274 17 at a lower
dose of 0.3 mg/kg and of CP-105,696 on PMN accumulation elicited by different
agonists, including LTB4 (500 pmollsite), PAF (1.9 nmollsite) and ZAP (3%).
SR-27417, at a dose of 0.3 mg/kg, significantly reduced PMN accumulation
induced by PAF 53% (P < 0.05), whereas CP-105,969 (10 mg/kg) did flot
significantly reduce PAF-elicïted PMN accumulation (29%, F> 0.05) (figure 3.6A).
When CP-105,696 (10 mglkg) and SR-27417 (03 mg/kg) were co-administered, an
additive inhibitoiy effect on PMN accumulation induced by PAF was observed (75%,
P < 0.001).
When LTB4 was used as an i.d. agonist, our resuits showed that CP-105,696
significantly inhibited PMN accumulation (79%, P < 0.01) (figure 3.6B). In contrast,
SR-27417 did flot affect LTB4-induced PMN accumulation. Furthermore, co
administration ofthe two drugs did not further inhibit LTB4—elicited PMN (82%, F <
0.01).
PMN accumulation elicited by ZAP (3%) was 42762 ± 8269 PMN per site in
vehicle-treated rats. The effect of SR-27417 (0.3 mglkg) and/or CP-105,696 (10
mg!kg) on PMN accumulation induced by ZAP (3%) was investigated. As shown in
figure 3.7, SR-27417 at a dose of 0.3 mg/kg tended to reduce PIVIN accumulation
induced by ZAP (30%, F> 0.05), whereas CP-105,969 (10 mglkg) tended to reduce
ZAP-elicited PMN accumulation (55% F> 0.05). When rats were treated with both
SR-27417 and CP-105,696, PMN accumulation induced by ZAP was fiirther reduced
by63%(F<0.05)
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skin
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Figure 3.7. Effect of SR-27417 (0.3 mg/kg) and/or CP-105,696 (10 mgfkg) on ZAP-elicited
PMN accumulation in rat dorsal skin
Data represent ffie mean ± SEM of 4-6 sites obtamed from 2-3 rats.
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3.2.3. Effect ofUK-74,505 and/or CP-105,696 on PMN accumulation
induced by chemically unrelated chemoattractants (TNF-Œ, IL-8
andZAP)
Intradermal PMN accumulation triggered by id injections of chemically
unrelated chemoattractants including TNF-Œ, IL-8 and ZAP was studied using
selective PAF (UK-74,505) and LTB4 (CP-105,696) antagonists.
PMN accumulation in response to TNF-Œ (50 pmollsite) was 93582 ± $121
PMN per site in vehicle-treated rats. Oral administration of CP-105,696 at a dose of
10 mglkg significantly reduced the accumulation induced by TNF-Œ by 42% (P <
0.05), while UK-74,505 (5 mglkg) tended to reduce the PMN accumulation by 15 ¾
(P> 0.05) (figure 3.$A). When UK-74,505 was co-administered with CP-105,696,
no significant effect on TNF-Œ-elicited PMN accumulation was observed.
PMN accumulation induced by IL-8 (50 pmollsite) was 119995 ± 14054 PMN
per site. In this experiment, neither CP-105,696 (10 mg/kg) nor UK-74,505 (5 mglkg)
significantly inhibited PMN accumulation induced by IL-8, (around 25%, P > 0.05)
(figure 3.8B). Co-administration of CP-105,696 (lOmg/kg) and 1.3K-74,505 (5
mglkg) also failed to inhibit the PMN accumulation induced by IL-$.
The effect ofUK-74,505 (5 mg/kg) and/or CP-105,696 (10 mglkg) on PMN
accumulation induced by ZAP (3%) was investigated. As shown in figure 3.9, UK
74,696 tended to reduce PMN accumulation induced by ZAP (5 5%, P > 0.05),
whereas CP-105,696 (10 mglkg) tended to reduce ZAP accumulation (41% P >
0.05). In the animais treated with UK-74,505 (5 mg!kg) and CP-105,696 (10 mg/kg)
PMN accumulation induced by ZAP was inhibited by 49% (P < 0.05).
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Figure 3.8. Effect ofUK-74,505 and/or CP-105,696 on TNf-a-elicited PMN accumulation
(A) & IL-8-clicited PMN accumulation (B) in rat dorsal skin
Data represent the mean ± SEM of 12-20 sites obtained from 6-10 rats.
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Figure 3.9. Effect of UK-74,505 andlor CP-105,696 on ZAP (3%)-elicited PMN
accumulation in rat dorsal skin
Data represent the mean ± SEM of 12 sites obtamed from 6 rats.
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3.3. Effects of PAF and LTB4 antagonists on oedema formation
elicited by different agonists
Intradermally injected PAF induced oedema formation in rat skin. Moreover
PAF and PGE2 act synergistically to induce oedema formation, as previously reported
by Wedmore and Williams (1981). Preliminary experiments were performed to
determine the optimal dose of SR-274 17 to reduce PAF-ïnduced plasma extravasation
in rat skin by 40-50 %. The optimal dose was found to be 0.3 mg/kg SR-27417.
Resuits were calculated by determining iii plasma extravasated from the 8-12
sites from 4-6 rats per group.
3.3.1. Effect of SR-27417 and/or CV-105,696 on oedema formation
elicited by PAF
As shown in figure 3.10, SR-27417 (0.3 mg/kg) signiflcantly reduced oedema
formation induced by PAF by 41% (F < 0.001), whereas CP-105,696, when
administered orally at a dose of 10 mg/kg, tended to reduce oedema formation
induced by PAF by 14% (P > 0.05). The animais pretreated orally with SR-27417
and CP-105,696 showed fisrther inhibition of the PAF-induced oedema formation
(50%, P < 0.001).
3.3.2. Effect of SR-27417 and/or CV-105,696 on oedema formation
elicited by LTD4 and substance P
To elucidate the role of PAF in contributing to the exudation of plasma
elicited by others inflammatoiy mediators over a 30 min test period, we have
investigated the effect of the selective PAF antagonist tSR-27417) on oedema
formation. When LTD4 was used as an agonist, pretreatment of rats with SR-27417
did flot significantly reduce the oedema formation (24%, P> 0.05). Similarly, there is
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no inhibitory effect of CP-105,696 (at a dose of 10 mg/kg) on the LTD4-induced
oedema (Figure 3.11A). However co-administration of SR-27417 (0.3mg/kg) and
CP-105,696 (lOmg/kg) significantly reduced LTD4-induced oedema (36%, P < 0.01).
Substance P (100 pmollsite), co-administered with PGE2 (250 pmollsite),
induced a small, but measurable, oedema in rat skin over a 30 min test period. As
observed with LTD4, the oedema induced by substance P was flot significantly
inhibited in rats pretreated orally with 0.3 mg!kg SR-27417 (28%, P> 0.05) (figure
3.1TB). In addition, CP-105,696 (at a dose of 10 mglkg) did flot affect the plasma
leakage induced by substance P. Co-administration of the two dmgs did flot ffirther
reduce skin oedema elicited by substance P.
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3.4. Effect of a PAF antagonist on the mïcrocirculatory blood flow in
rat skin
Local microcirculatory skin blood flow before the injection of either the
agonist or vebicle was very similar, around 24 (arbitrary scale) as shown in figure
3.12 and 3.13. The intradermal injection ofthe vehicle (HBSS BSA 0.1%) induced a
slight increase (20%) in skin blood flow. In rats, this trauma-induced increase in
blood flow was transient and lasted for less than 3 min.
Figure 3.12 and 3.13 are representative examples of the vasodilator response
to LTB4 and PAF. Injection of LTB4 i.d. at dose of 1000 pmol!site induced a stable
vasodilatory response which lasted for 3-6 mm, as observed by an increase in skin
blood flow. Similar vasodilatoiy effect occurred when PAF (3.8 pmollsite) was
injected i.d.
SR-27417 pretreatment inhibited blood flow elevation elicited by
intradermally injected PAF (figure 3.12). The vasodilator effect of PAF (3.8 nmol)
was reduced by 48% at a 0.3 mg/kg dose ofSR-27417 and by 58 % at a 1 mg!kg
dose.
Figure 3.13 shows the effect of SR-27417 on LTB4 (1000 pmollsite) induced
elevation in blood flow. Interestingly, SR-27417 at a dose of 0.3 mg/kg also reduced
the skin blood induced by LTB4 by 35 %.
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4.1. Problem situation
The local release of chemotactic and stimulatory factors triggers the moiecular
events that drive the migration of PMNs to the site of inflammation. These factors
include chemokines, cytokines, complement-derived protein fragments, lipid
mediators and bacterial products such as formylated peptides which coordinate the
cytoskeletal rearrangements and adhesion changes essential for effective celi motility.
Lipid mediators play a pivotai role in regulating PMN extravasation at the
blood endothelium interface, by regulating, for instance, vascular permeability,
vasodilation, and/or endothelial ceil hyperadhesiveness for neutrophils (Marleau et
al., 1999). Bioactive lipid mediators including, LTs and PAF, are produced by the
invading PMN themselves.
We have proposed that lipids mediators, particularly LTB4, LTD4 and PAF
participate in PMN activation by interacting with PMN themselves (autocrine
activation) and/or with the endothelium to stimulate cellular events that promote and
facilitate the transmigration process ofPMNs. Blocking ofthe activity ofone ofthese
mediators has been shown to exert a significant, but only partial, effect on
transmigration. We propose that the concommittant blockade of the activity of PAF
and LTB4 may have a synergistic or additive effect and a more profound impact on
PMN migration. Different experimental approaches were developed to confirm our
hypothesis and delineate the role of PAF and LTB4 in neutrophil trafficking.
4.2. Methodology considerafions
The experimental model used in our study is dermal inflammation in the male
Sprague-Dawley rat (Charles River, Québec). The model is very convenient for i.d.
injections of the chemotatic factors and the study of PMN migration to the site of
inflammation. One ofthe advantages is that we can perform many injections in the rat
dorsal skin and consequently, we can test various agonists in the same animal.
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Rabbits could have been useful for this purpose but the rat is an economical model. In
addition, the LTB4 antagonist (CP-105,696) used in our protocol is active in rats and
flot in rabbits (Showeli et aL, 1995).
Rats were injected with G-C$F (fiigrastim or NeupogenMD) at a dose 5 g/kg
for 9-1 1 days before doing the experiment. G-CSF was injected to increase the
number of circulating PMN in the rats. When we started our studies we did flot use
G-CSF and we observed that the number of circulating PMN was very low. We then
followed the kinetics ofblood PMN accumulation using G-CSF and found that there
was a 5 to 6-fold increase in blood PMN numbers, most of which were presumably
released from the bone mari-ow following G-CSF treatment (Valente et al., 2002).
The increase in circulating PMNs in response to G-C 5F injection in rats was
associated with a proportional increase in the local accumulation of PMN to
chemoattractants, allowing us to assess the effect of dmgs on agonist-induced PMN
accumulation in a quantitative mariner.
To study the role of PAF and LTB4 in regulating neutrophil trafficking in
response to locally injected chemoattractants, we have used two selective PAF
antagonists, UK-74,505 and SR-27417 and one LTB4 antagonist, CP-105,696 (the
only selective LTB4 antagonist available for in vivo studies). BIIL 284, a potent and
selective LTB4 antagonist that has recently been made available by Boehringer
Ingeiheim, Germany will be used in future studies.
Dmgs were given orally to the rats, as this mode of administration is
noninvasive in contrast to i.v. administration. The optimal doses of the dmgs were
chosen according to our preliminary experiments. For instance, CP-105,696 has been
administered orally at a dose 10 and 30 mg/kg in a suspension of 0.5% CMC 16 h
prior to the i.d. injections of agonists, because ofthe extremely long haif-life of the
dmg in this species (t = 16-1$ h), (Showeli et al., 1995). In contrast, UK-74,505 and
$R-27417 were adminïstered orally 2 h before the i.d injections ofagonists due to the
short haif-life of these dmgs. SR-27417 for example, was absorbed optimally 3 h
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afier oral administration in mice and rabbits (Herbert et al., 1991; Herbert et al.,
1992). These drugs were given at relatively lower doses than for CP-105,696 (up to 1
mg/kg for SR-27417 and 5 mgfkg for UK-74,505). The apparent lower potency of
CP-105,696 may be attributed, at least in part, to the high level of protein binding of
the compound in whole blood (Showeil et al., 1998). High plasma protein binding is
also likely to contribute to the remarkably long plasma haif-life of CP-105,696, seen
in both animals and human phase I ciinical studies (Liston et al., 199$; Showeil et al.,
1998).
In order to confirm our observations, we have used two selective, chemically
unrelated PAF antagonists; UX-74,505 and SR-27417. The potency ofthe two drugs
is slightly different. SR-27417 bas been shown to be a highly potent, specific and
competitive PAF receptor antagonist that is about 120 times more potent than WEB
2086, another PAF receptor antagonist, in vivo. In contrast, UK-74,505 was 10-30
times more potent than WEB-2086 as an inhibitor of PAF-induced hypotension in
rats (Herbert et al., 1992; Parry et ai, 1994).
A skin bioassay model has been used to determine PMN accumulation in
response to intradermally injected agonists, including chemokines, cytokines and LPS
as described previously (Marleau et al., 1996; Marleau et al., 1999). Different
methods can be used to assess PMN accumulation in a quantitative manner. One of
these methods requires the use of radioactive labeled PMI’[s, harvested from a donor
animal, and radiolabeled before injection into a recipient animal. For example, 51Cr-
labeled PMNs and “In-labeled PMNs were used to determine PIVIN accumulation in
different species like rabbits (Marleau et al., 1999), and rats (Sanz et al., 1995).
Mternatively, we may use an enzyn;atic marker, such as the MPO content of PMNs
to quantify PMN accumulation. In this proposai, we have assessed PMN
accumulation using the MPO assay to minimize the number of animais to be used (no
donor animais for ceil labeling). In addition, the MPO assay is a simple and
reproducible technique (Kitahara et ai., 1979), economic when compared to the use of
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radioisotopes, and that limits radioactive waste products. Moreover, PMN-labeling
with 51CrO4 has been found to be quite variable and unreliable (Stark et al., 1992).
Local oedema formation elicited by locally injected chemoattractants was
measured by the Evans blue assay. Briefly, Evans blue injected i.v. binds to plasma
albumin, and extravasate with albumin at the sites of increased vascular permeabllity,
appearing as a blue dot on the dorsal skin of the rat. Evans blue is extracted from the
skin sites with DMF, and quantified by measuring the absorbance at 630 nm (with
reference wavelength at 450 nm) (Takano et al., 1998). Work in different laboratories
has assessed local skin oedema in different species including rats, rabbits and guinea
pigs by the i.v. injection of human semm albumin (HAS) labeled with 125j (Sanz et
al., 1995; Norman et al., 1997; Teixeira et al., 1994), or labeled with 99mTc (in
domestic pigs) (Chan and Ford-Hutchinson, 1985). Mtematively, other groups have
used Evans blue extravasation to assess, either qualitatively or quantitatively, skin
oedema (Flower et al., 1976; Souza et al., 2000; Souza et al., 2002; Souza et aÏ.,
2003). k our studies, we have used Evans blue as a marker ofprotein extravasation in
order to limit radioactive waste products and also because the radioactive materials
are mucli more expensive.
Intradermally inj ected chemotactic mediators increase vascular permeability
as a resuit of activation and accumulation of PMN (Wedmore and Williams, 1981;
Bjork et al., 1982). This effect usually is potentiated by PGE2. Ail agonists were co
injected with PGE2 (250 pmol), used as a vasodilator in order to enhance PMN
extravasation to the skin (Movat et al., 1984; Wedmore and Williams, 1981), which
may be relatively low in rat species compared with other species such as rabbits
(Marleau S. unpublished observations).
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4.3. Role of LTB4 in PMN accumulation at cutaneous sites
The intradermal injection ofLTB4 into guinea pig dermis has previously been
shown to induce time- and concentration-dependent infiltration of neutrophils
(Fretland et al., 1989; Pettipher et al., 1993; Showeli et al., 1995). This observation
has been confirmed in the rat model. In addition, LTB4- induced PMN accumulation
was reduced in a dose-dependent manner by the selective LTB4 antagonist, CP
105,696 (figure 3.1).
In the present studies, CP-105,696 was used as a pharmacologic tool to
investigate the role of LTB4 in PMN accumulation and oedema formation elicited by
a variety of inflammatory mediators including LTB4. Our resuits showed that the oral
administration CP-105,696, at doses of 10 and 30 mglkg, significantly and dose
dependently inhibited LTB4-elicited PMN accumulation and tended to reduce PAF
induced PMN accumulation (by —30%) as shown in figures 3.4 and 3.6.
Previous observations supported a role for 5-LO products in the local
accumulation of neutrophils in dermal inflammation (Marleau et al., 1999). for
instance, PMN accumulation in rabbit skin was significantly reduced by a
pretreatment of animals with MK-0591 (a 5-LO product synthesis inhibitor).
Goldman et al. (1990) also showed that an i.v. pre-treatment of rabbits with the LO
inhibitor diethylcarbamazine prevented PMN accumulation into skin blisters filled
with either LTB4 or with plasma collected from the ischemic hindlimbs of rabbits
which contained elevated levels ofLTB4.
In addition, a role for LTB4 in stimulating neutrophil chemotaxis in different
pathologic contexts is supported by a number of studies. for example, Turner et al.
(1996) found that the in vivo treatment of monkeys with CP-105,696 significantly
reduces the increase number of BAL neutrophils afier Ascaris suum antigen
challenge. Grifflths et al. (1995) also studied the role of LTB4 in the progression of
collagen-induced arthritis and showed a strildng efficacy of CP-105,696 in a murine
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model. Showeli et al. (1995) reported that CP-105,696 inhibited PMN (ami
eosinophil) infiltration in guinea pig skin induced by LIB4, arachidonic acid and by
the monooxygenase product 12(R)-EffilE (which also acts at the BLTR) in a dose
dependent manner, with an ED50 of 0.3 ± 0.1 mglkg p.o.
In order to delineate the role of LTB4 in mediating or regulating PMN
accumulation eiicited by various chemically unreiated chemotactic stimuli inciuding
TNF-Œ, IL-8 and ZAP, we pretreated the animais with the CP-105,696 compound.
Our resuits showed that CP- 105,696 significantiy reduced PMN accumulation elicited
by TNF-a. by 42% (P < 0.05) and tended to reduce ZAP-induced accumulation, but
did flot significantly reduced the accumulation induced by W-8 (figures 3.8 and 3.9).
Ail these studies were performed in a single animal species, the rat, and it cannot be
excluded that similar experiments pefformed in other species may yieid siightly
dillerent resuits. for example, in previous studies, Dr. Marleau (1999) has shown that
IL-8-induced ?MN migation in rabbit can be significantly reduced by treatment with
a ieukotriene biosynthesis inhibitor or foliowing desensitization of LTB4 receptors,
suggesting that in the rabbit, in contrast to the rat, LYB4 seems to play a role in IL-8-
induced PMN migration. TNF-Œ may induce neutrophul accumulation in part via the
release of LTB4. Indeed, previous studies showed that in a model of ovalbumin
sensitized mice, the i.p. administration of TNF-Œ induced neutrophil migration in a
LTB4-dependent manner, inasmuch as PMN accumulation was inhibited by 86% afier
pretreatment of the mice with MK-886 (a LTB4 synthesis inhibitor) (Canetti et ai.,
2001).
Our resuits support an important role for LTB4 in mediating neutrophil
accumulation in dermal inflammation, in agreement with observations in other
inflammatory models such as in a model oftransient ischemia and reperfusion injury
of the superiof mesenteric artery in rats, which showed that post-ischemic treatment
with CP-105,696 inhibited neutrophil accumulation in the intestine and mesentery,
suggesting that LTB4 may play an important role in mediating neutrophil-dependent
local ischemia and reperfusion injury (Souza et al., 2000). However, the relative
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importance of LTB4 contribution to the tissue injury in this model is stili uncertain
(Souza et al., 2002).
4.4. Role of PAF in PMN accumulation and oedema formation at
cutaneous sites
In the present study, the long-acting and selective PAF receptor antagonist,
UK-74,505 (Alabaster et al., 1991) was employed to investigate the possible
contribution of endogenous PAF to PMN accumulation in rat skin in response to
soluble mediators.
Oral administration of 1.3K-74,505 reduced PMN accumulation elicited by
intradermally—injected PAF (51% F < 0.05), and tended to reduce LTB4 and ZAP
induced PIVIN accumulation (figures 3.4 and 3.9). However, this PAF antagonist did
flot prevent PMN accumulation induced by TNF-Œ and IL-8 (figure 3.8).
In agreement with our resuits, Sanz et al. (1994) reported that i.v. UK-74,505
blocked neutrophil and eosinophil accumulation and oedema formation induced by
PAF in guinea pig skin but had no significant effect on the responses elicited by
LTB4 or ZAP.
In a previous study, it has been shown that whule PAF caused little or no
neutrophil accumulation in rabbit skin, it caused marked oedema formation,
particularly when co-injected with PGE2 (Norman et al., 1997). Interestingly, only
oedema was reduced by pretreatment ofthe animais with UK-74,505. These findings
are not consistent with our data and with data from other studies showing that the
PAF antagonist, L-659,989, reduced neutrophil accumulation in reversed passive
Arthus (RPA) reaction in rabbit skin (Helleweil, 1990). Norman et al. (1997)
explained this finding by suggesting that PAF may be rapidly metabolized locally,
and/or that the lack of effect of the antagonist on PMN accumulation may be due to
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failure of the dmg to reach the site of action at the appropriate time rather than a lack
ofbioactivity.
To further delineate the role of PAF in PMN accumulation and oedema
formation in rat skin in response to different inflammatory stimuli, we also tested the
effect of the potent and selective PAF antagonist $R-27417 on PMN accumulation
and oedema formation elicited by PAF and other mediators. Interestingly, the resuits
of our study confirmed our previous resuits with UK-74,505, inasmuch as orally
administered SR-27417, at a dose of 0.3 mg/kg, significantly reduced PMN
accumulation elicited by PAF by 53% (P < 0.05) (figure 3.6) and tended to reduce
ZAP- elicited PMN accumulation (figure 3.7). No significant effect was observed on
LTB4-induced PMN accumulation. Yet, inhibition ofPMN accumulation by the LTB4
receptor antagonist alone inhibited up to 78-79% of LTB4-induced PMN
accumulation, which may have been too high to observe either an additive or a
synergistic effect of both LTB4- and PAF-receptor antagonists on PMN
accumulation. Additional studies, using a lower dose of the CP-105,696 antagonist,
may be necessary to resolve this issue.
Acute oedema being one ofthe most important initial feature of inflammation,
we therefore examined the role of PAF in mediating agonist-induced oedema in rat
skin by studying the effect of SR-27417 in protecting rats from agonists-induced
oedema. As expected, SR-27417 (0.3 mg/kg) significantly reduced oedema formation
elicited by PAF (41% F < 0.001) (figure 3.10). SR-27417 was highfy selective for
PAF since it did flot significantly altered oedema formation evoked by a range of
other inflammatory mediators such as LTD4 and substance P (figure 3.11). In
agreement with our data, Herbert et al. (1992) concluded that SR-2741 7 prevented the
increase in vascular permeability associated with the local allergic reaction,
confirming the role of PAF in this acute inflammatory reaction. Additional previous
studies showed that SR-274 17 has a modest inhibitory effect on the late asthmatic
response, suggesting that PAF has a small role in allergic inflammation (Evans et al.,
1997). In addition, a number of studies have implicated PAF as an important
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mediator in an immune complex-mediated inflammation (RPA reaction) (Williams et
al., 1986; Pons et al., 1993; Rossi et al., 1992). PAF also appears to play an important
foie in intestinal ischemia and reperffision (I/R)-induced tissue injury, as sbown in a
modei of intestinal I!R (Souza et al., 2003). In that model, use ofeither PAF receptor
deficient mice or PAF receptor antagonist attenuated tissue injury, suggesting a role
for PAF in that model.
In contrast, other recent studies showed that the PAF receptor do flot play a
major role in lung injury secondary to pulmonary infection with gram negative
bacteria (KÏebsietla pneumoniae) in mice, inasmuch as inoculation of this bacteria
induced an increase in the number of infiltrating neutrophils and in the generation of
pro-inflammatory cytokines in the lung of infected mice that was flot prevented by
administration of the PAF receptor antagonist UK-74,505 suggesting that PAF, by
acting on its receptor, do not play a major role in the local production of chemokines
and recruitment ofthe leukocytes (Soares et al., 2002).
To summarize our observations on the role of PAF in mediating local oedema
in response to different agonists, we could flot show the role for PAF in contributing
to the local oedema evoked by substance P and LTD4. However, a number of studies
have shown a role of PAF in different pathologic conditions, suggesting that
additional studies should be performed wïth additional substances known to increase
vascular permeability such as bradykinin, histamine and serotonin. It may also be that
the contribution of PAF to local oedema in response to agonists may be related to the
PMN extravasation process, and could be more apparent with agonists such as LTB4.
Unfortunately, we have flot been able to elicit significant local oedema with up to 3
nmol/site of LTB4 inj ected intradermally in rat skin.
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4.5. Role of LTB4 and PAF in PMN accumulation and oedema
formation at cutaneous sites
The combination of PAF and LTB4 antagonists has been employed to assess
the co-operative effect of PAF and LTB4 in PMN accumulation and oedema
formation in dermal inflammation induced by a variety of agonists. Our resuits
revealed that the co-administration of CP-105,696 and UX-74,505 had an additive
inhibitory effect on PMN accumulation induced by PAF but not by LTB4 (figure
3.4). These resuits were confirmed by the co-administration of$R-27417 (0.3 mglkg)
and CP-105,696 (figure 3.6). Interestingly, both agonists are synthesized within PMN
and exert autocrine and paracrine effects on neutrophils and/or neighboring ceils such
as endothelial ceils (McDonald et al., 1994). Our resuits suggest that both mediators
exert additives effect in regulating PIvJN extravasation at the blood-endothelium
interface, more particularly when PAF is used to elicit PIvIN accumulation. Our
resuits are less conclusive for LTB4-elicited PMN accumulation, but as mentioned
before, h could be due to a bias in our experimental protocol (too high dose of CP
105,696). Additional studies are undergoing in our laboratories, using a lower dose of
the CP compound as welt as an additional selective LTB4 receptor antagonist.
Other recent studies demonstrated a role of lipid mediators in hypoxia
induced microvascular inflammatoiy responses using PAF and LTB4 antagonists. In
contrast, no additive effect was observed in leukocyte emigration and the increase in
vascular permeabllhy when both PAF receptor antagonist (WEB-2086) and the LTB4
receptor antagonist (LTB4-dimethyl amide) were administered simultaneously
(Casillan et al., 2003).
Administration of SR-27417 and CP-105,696 siguificantly attenuated PAF
induced PMN accumulation and vascular penneability, and both agents had a
stronger effect on PMN accumulation (figure 3.6A) than on vascular permeability
(figure 3.10). This pattem may indicate that medïators other than PAF and LTB4 are
largely responsible for change in vascular permeability and/or that such permeability
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changes may resuit from leukocyte-dependent and leukocyte-independent
mechanisms.
To our knowledge, it is the first time that an additive effect for PAF and LTB4
in inducing PMN accumulation is shown in vivo.
In summary, our findings support the previously proposed hypothesis that in
activated PMN, PAF and/or LTB4 biosynthesis represents an important amplification
mechanism regulating PMN and plasma extravasation at the blood-endothelium
interface as summarized in figure 4.1 (Marleau et al., 1999). The mechanism of
action PAF andlor LTB4 depends on PMN chemoattractant receptor engagement
which resuits in the activation of the 5-LO pathway. This involves a rapid Ca2-
dependent redistribution of the enzyme from its location in resting cel! to a nuclear
membrane compartment afier agonist activation. This process of translocation could
reasonably be assumed to bring the enzyme to its membrane-derived substrate.
cPLA2 acts to release arachidonate from the nuclear envelope phospholipids (Peters
Golden and Brock, 2000). Arachidonate binds to FLAP, an integral nuclear envelope
protein, to facilitate its processing by 5-LO. This leads to LTA4 biosynthesis which
can be either metabolized to LTB4 or released and used by other ceils such as PMN,
endothelial ceils and platelets to form lipoxgynase products independently of the
nature of chemoattractant involved (figure 4.1). In agreement with such hypothesis, it
has been reported that PMN responsitivity to chemoattractants is necessary for the
emigration process in vivo (Nourshargh and Williams, 1990) and that PIV1N agonists
(C5a, IL-8, FMLP, PAF and LTB4 itselt) stimulate LTB4 biosynthesis in PMN
(McCoIl et al., 1991; McDonald et al., 1992; Marleau et al., 1999). Altematively,
PMN agonists may also lead to PAF biosynthesis and secretion (Sisson et al., 1987;
Bauldry et al., 1991; Watanabe et al., 2003). The LTB4 and/or PAF generated may
then ligate their receptors either on PMN (autocrine manner) or on endothelial celis,
and trigger events that are important for transendothelial migration such as regulation
of PMN-endothelium adhesive interaction or possibly endothelial celis retraction
(Marleau et al., 1999). In this scenario, activation of 5-LO and ligation of PAF and
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Figure 4.1. Hypothetical scheme of events for the involvement of 5-LO products and
PAF in the regulation ofPMN trafficking to inflammatory sites
R, receptor; BLTR, LTB4 receptor, ALXR, LXA4 receptor; CysLTR,
cysteinyl LT receptor; cPLA2, cytosolic phospholipase A2, 12-LO, 12-
lipoxygenase; I 5-LO, 1 5-lipoxygenase; FLAP, 5-LO activating protein;
Ai-H, LIA4 hydrolase; C4-S, LIC4 synthase.
XItJTROPIIIL
ENDOI’1tILIAI.
CEIL
from Marleau et aI. (1999) Journal oflrnmunotogy, 163: 3349—345$.
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LTB4 receptors represent common events in the mechanism of PMN emigration
elicited by soluble chemoattractants. Consequently inhibition of 5-LO activation by
blocking of the LTB4 and/or PAF receptors would be expected to down-regulate
PMN chemotaxis to most PMN agonists, in agreement with the data reported herein.
The resuits obtained in this work support a role for PAF and/or LTB4 in
regulating PIvIN extravasation elicited by a number of inflammatory mediators at the
blood-endothelial interface. In addition, PAF and LTB4 exert a co-operative effect in
inducing PMN accumulation in vivo. These observations could be of potential value
for future anti-inflammatory dmg development.
4.6. Perspectives
We believe that the resuits obtained in these studies have provided a better
understanding of the biological significance of lipid mediators, particularly PAF
and LTB4, in neutrophil trafficking. Future studies, using a different selective
LTB4 receptor antagonist, will help to clarify unresolved issues.
In addition, ffirther studies are required to delineate the role of PAF and LTB4
in mediating microcirculatoiy skin blood flow changes, elicited by a variety of
agonists, using selective and highly potent PAF and LTB4 antagonists.
47. Conclusion
In conclusion, this study provides novel information regarding the role oflipid
inftammatory mediators in the regulation of neutrophil trafficking to inflammatory
lesions.
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We have been able to document the following findings:
1. LTB is involved in PMN emigration and plasma extravasation
elicited by LTB4 and other soluble agonists (PAF, ZAP and TNF-Œ).
2. PAF is involved in PMN emigration and plasma extravasation elicïted
by PAF and other soluble agonists (ZAP).
3. PAF and LTB4 may act co-operatively at the blood-endothelial
interface to regulate PI\IN extravasation, inasmuch as PAF and LTB4
receptor anatgonists exerted an additive effect in reducing PMN
accumulation at dermal inflammatory sites in rats.
4. The chemotactic effect of PAF appears to involve, at least in part, 5-
LO activation and BLT receptor signaling on circulating neutrophils
and/or endothelial ceils.
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